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ABSTRACT OF THE DISSERTATION 
Single-chain RANKL Provides Insights into RANK Receptor Oligomerization and a Novel 
Approach to Osteoclast Inhibition 
by 
Julia Therese Warren 
Doctor of Philosophy in Biology and Biomedical sciences 
(Immunology) 
Washington University in St. Louis, 2015 
Professor Steven L. Teitelbaum, Chairperson 
 
Osteoporosis is a skeletal disease characterized by bone resorption in excess of bone 
formation. The osteoclast is the sole bone resorbing cell and therefore provides an important 
avenue for novel therapeutic development. The mature osteoclast is derived from the 
monocyte/macrophage lineage, and its proper differentiation and function requires the interaction 
of receptor activator of NF-kB Ligand (RANKL) with its receptor RANK. RANKL exists as a 
homotrimer, with classical models of receptor activation assuming trimeric clustering of receptor 
as necessary for signal transduction. We have designed a novel single-chain RANKL 
(scRANKL) construct to test the assumption that the recruitment of three RANK receptors is 
necessary for downstream signaling.  scRANKL consists of all three RANKL monomers  
connected by  short, protease-resistant linkers, enabling individual manipulation of each RANK 
binding site and assessment of the receptor clustering state necessary for downstream signaling.  
We used our co-crystal structure of RANK/RANKL to design mutations in RANKL that abolish 
binding to RANK.  After inserting these variants at one scRANKL site, to create a single-
 ix
blocked ligand capable of recruiting only two RANK receptors, we still observe RANK signaling 
and osteoclast formation, although only at high ligand concentrations.  In contrast, double-
blocked scRANKL does not form osteoclasts.  Hence, dimeric engagement of RANK by 
RANKL is sufficient and necessary for downstream signaling.  Although double-blocked 
scRANKL may potentially antagonize RANK/RANKL signaling, it competes poorly with 
endogenous RANKL due to loss of receptor avidity.  Therefore, we identified mutations in 
RANKL, using yeast surface display, that dramatically increase its affinity for RANK.  
Concurrently, we sorted for loss of binding to OPG, the RANKL endogenous decoy receptor, 
with the hypothesis that this trait would allow scRANKL to more efficiently function as a 
competitive antagonist, in vivo.  When inserted at the intact RANK binding sites in single- or 
double-blocked scRANKL, these novel constructs are highly efficient inhibitors of wild-type 
RANKL-induced osteoclastogenesis.  Our work demonstrates that the manipulation of RANK 
receptor oligomerization, and the subsequent blockade in signaling, may provide a novel avenue 
to develop anti-resorptive drugs.  Additionally, the design of single-chain TNFSF ligands with 
individually manipulated receptor binding sites can more broadly inform our knowledge of how 
these receptors, with diverse biological functions, initiate signal transduction. 
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Chapter 1 
 
Introduction 
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1.1 Background 
Bone homeostasis 
The skeletal system in mammals acts not only as a scaffold whose biomechanical 
properties are crucial for movement and mineral homeostasis, but also as a key site for the 
development and maintenance of hematopoietic lineage cells (1).  More recently, it has been 
suggested that the skeleton acts as an endocrine organ to regulate whole organism metabolism 
(2). Classically, basal conditions within the skeleton were thought to be maintained by a balance 
between the bone anabolic osteoblast and the bone resorptive osteoclast (3).  It is now 
appreciated that the osteocyte, itself a terminally differentiated osteoblast, plays a critical role in 
sensing mechanical stress and perhaps in regulating other cell types within the bone marrow 
cavity (4).  Both the osteoblast and the osteocyte are derived from bone marrow stromal cells, 
and their crucial roles in the synthesis and mineralization of bone matrix have been extensively 
studied (5). 
The osteoclast is a multinucleated cell derived from hematopoietic lineage 
monocyte/macrophages precursors (6).  Osteoclasts act to resorb bone by attaching via the 
recognition of matrix-embedded "RGD" ligands binding to the avb3 integrin (7-9).  Subsequent 
signaling leads to actin cytoskeletal organization, the formation of an actin-rich sealing zone, and 
finally the generation of a ruffled plasmalemma border juxtaposed to bone (10, 11).  The 
directional secretion of acid- and collagenolytic enzyme-containing vesicles into the resorptive 
area promotes dissolution of the inorganic phase of bone, followed by proteolytic cleavage of the 
demineralized, organic component (12).   
A long-standing question regarding skeletal homeostasis is how osteoclastic bone 
resorption and osteoblastic bone formation are coupled in time and space.  It is believed that 
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bone formation is directed to areas of recent, active bone resorption thus providing a mechanism 
by which older, less mechanically sound bone can be equally replaced by new bone (13, 14).  
This phenomenon has been recognized for decades (15), and recent efforts have pointed to 
several candidate factors that may act to link these two processes (16-20).  Although the precise 
molecular mechanisms governing this aspect of bone homeostasis, it is clear that a balance 
between these two processes is essential. 
 
Diseases Resulting in Low Bone Mass 
Although in basal conditions of skeletal homeostasis the actions of the bone anabolic 
osteoblast and the bone catabolic osteoclast are quantitatively balanced to maintain skeletal 
mass, many diseases reflect an imbalance toward osteoclast activity.  Among these are 
osteoporosis or the lytic lesions of skeletal metastases, and rheumatoid arthritis.  In particular, 
post-menopausal low bone mass and osteoporosis are estimated to affect roughly over 50 million 
Americans.  Decreased bone mass attending a decline in estrogen levels fuels primarily an 
increase in osteoclastic bone resorption that osteoblastic bone formation is unable to compensate 
for (21).  These diseases predispose to fragility fractures, likely reflecting not only a decrease in 
bone mineral density but also compromised bone quality reflected in such parameters as thinning 
of trabeculae and loss of trabecular connectivity.  Additionally, pathologies such as Paget's 
disease of the bone reflect focal, increase bone turnover with a balance toward resorption (22). 
 
Role of RANK, RANKL and OPG in regulating osteoclasts  
Several cytokines influence the formation and function of osteoclasts, but nearly 15 years 
ago a series of genetic studies demonstrated the interaction of receptor activator of NF-kB ligand 
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(RANKL) with its receptor RANK to be key molecular events necessary for these processes (23-
26).  Around the same time, osteoprotegerin (OPG) was described as a decoy receptor for 
RANKL, preventing its association with RANK and thus inhibiting osteoclast formation and 
function (27, 28).  Reflecting the role of the RANK/RANKL/OPG axis in bone homeostasis, 
humans with inactivating mutations in RANK or RANKL can present with osteoclast-poor 
autosomal recessive osteopetrosis (ARO) (29).  This disease is characterized by impaired 
remodeling, retention of mineralized cartilage, high bone mass and an absence of tartrate-
resistant acid phosphatase (TRAP)-positive osteoclasts on histological sections (30).  
Conversely, mutations in OPG result in idiopathic hyperphosphatasia, also known as juvenile 
Paget’s disease (31).  This diminished functionality of OPG causes a state of high bone turnover 
with hyperactivated osteoclasts and concomitant increased osteoblast activity.  Progressive long 
bone deformities and predisposition to fracture are the result of overall low bone mass.  Table 1.1 
summarizes currently identified mutations affecting the regions encoding the cytokine/receptor 
interface. 
 
Tumor Necrosis Factor Superfamily   
RANKL is a member of the tumor necrosis factor superfamily (TNFSF) and both RANK 
and OPG are members of the TNF receptor superfamily (TNFRSF).  There are at least 19 
TNFSF cytokines and 30 receptors in humans displaying low sequence conservation with high 
degrees of structural homology (32).  The available TNFSF structures all show the cytokine as 
homotrimers (reviewed in (33), see also (34-39)) composed of two layered beta sheets named 
from N- to C-terminal as the A through H sheets with connected loops likewise termed the AA’, 
A’B, BC etc. loops. The A’/A/H/C/F sheet is mostly buried, forming a hydrophobic core thought 
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to be important for trimer stability, whereas the B’/B/G/D/E is less buried. Loops connecting the 
beta sheets face outward from the core of the protein, comprising most of the binding interface 
formed between two adjacent monomers.  All TNFSF members are Type II transmembrane 
proteins, and in some cases are thought to take on soluble forms after either cleavage off of the 
cell surface or through alternative splicing.   
RANKL is a member of the so-called “conventional” TNFSF ligands, along with TNF , 
lymphotoxin alpha (LT ), LT , tumor necrosis factor-related apoptosis inducing ligand 
(TRAIL), FasL, TNF-like ligand 1A (TL1A), lymphotoxin exhibiting inducible expression and 
competing with herpes simplex virus glycoprotein D for herpesvirus entry mediator a receptor 
expressed by T lymphocytes (LIGHT), and CD40L.  Conserved elements among this family are 
hydrophobic residues in the DE loop, relatively long CD, DE, and EF loops, and a footprint for 
the receptor with two clustered contact areas (33, 40).  The other loop making substantial contact 
with receptor, the AA’ loop, varies in length wildly among TNFSF members from 6 residues 
(TNF ) to 22 (TRAIL).  Among TNFSF member, RANKL is most closely related to TRAIL, 
sharing 25% sequence identity between murine and 27% between human cytokines (aligned 
using ClustalW (41)).  The structures of human RANKL (3URF) and human TRAIL (1DG6) 
align with a C  root mean square difference (RMSD) of 1.31Å, indicating substantial overall 
structural homology (alignments performed using PDBeFold (42)).  Indeed, TRAIL likely is also 
capable of binding OPG, though at low affinity (43, 44), and clusters phylogenetically with 
RANKL as a distinct family among the TNFSF (45). 
 
Tumor Necrosis Factor Receptor Superfamily  
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The extracellular portion of TNF receptors consists of modular cysteine-rich domains 
(CRDs) with varying numbers of intramolecular disulfide bonds (46).  These receptors are 
primarily type I transmembrane proteins and take on an elongated, rod-like shape of between one 
and four CRDs.  Although less well structurally studied than the TNF ligands, most TNF 
receptors are thought to be monomeric in nature.  A notable exception is the observation of a 
TNFR1 dimer when crystallized alone, either in a head-to-head or head-to-tail orientation (47).  
How relevant this TNFR1 dimer is to the control of receptor signaling remains to be established.   
RANK and OPG both contain four extracellular CRDs, and despite having only 34% 
sequence similarity, individual superposition of the CRDs yields Ca RMSDs between 0.9 and 
1.5Å (34).  Though they occupy a similar overall binding grove, we were able to identify several 
key differences in the individual residues used to make contact with RANKL.  Specifically, OPG 
makes more extensive contacts to the DE loop and also possesses a key binding determinant at 
residue, F96.  This residue participates in pi-stacking interactions with portions of the RANKL 
CD loop, which undergo a significant rearrangement in this area to accommodate OPG. Indeed, 
the corresponding residue F117 in humans is mutated in several reported cases of juvenile 
idiopathic hyperphosphatasia (Table 1.1). Conversely, the interaction with RANK requires no 
substantial rearrangements of RANKL and the receptor appears to be shifted slightly away from 
the RANKL DE-loop side of the interface.   
Additionally, a key difference between RANK and OPG lies in their C-terminal regions.  
Following its CRDs, RANK contains a transmembrane region and a long cytoplasmic motif with 
TNF receptor-associated factor (TRAF) recruitment motifs (48, 49).  Its signaling is described 
below. OPG, however, is secreted and capable of forming a homo-dimer through its C-terminal 
region, especially the death-like domains and the penultimate C400 residue (50).  OPG also 
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contains a heparin-binding basic region, which has been implicated in the sub-cellular 
localization of RANKL in osteoblastic cells (51).  Interestingly, several patients with juvenile 
Paget’s diseases have mutations disrupting both the death-like domain and the heparin binding 
domains (31, 52-54).  However, these patients are also missing the crucial regions for OPG 
dimerization. It remains to be seen which role of OPG (as a highly avid decoy receptor or as 
regulator of RANKL trafficking) are functionally significant in light of these mutations.   
 
Binding of RANKL to RANK or OPG 
We previously determined the single-site binding affinities of RANKL for both RANK 
and OPG (34) using surface plasmon resonance (SPR).  In these experiments, the monomeric 
fragments of each receptors containing the cytokine-binding CRDs was used as the analyte, thus 
allowing us to measure the kinetics of how RANK or OPG bind to an individual cleft within the 
trimer.  From these experiments, we observed that RANKL binds to RANK with approximately 
2uM affinity.  This is reflected in a relatively slow on-rate and fast off-rate (see Table 1.2).  
Conversely, the single-site affinity of OPG for RANKL is almost 500-fold higher at 
approximately 5nM.  For OPG, association and dissociation rates are 30-fold faster and 20-fold 
slower, respectively.  These values are consistent with the function of OPG as a decoy receptor.  
Measuring single-site affinities of OPG for RANKL necessitated using only the ligand-binding, 
CRDs of OPG rather than the full-length molecule which is known to form a homodimer.  From 
our data, we cannot determine whether one full-length OPG homodimer is capable of binding to 
grooves on two separate RANKL trimers, or whether each arm of the full-length OPG dimer 
binds to two distinct grooves within one RANKL homotrimer. 
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The values that we measured for these interactions varied from previously reported ones 
(35, 36).  It is important to note that our experiments address single-site binding, rather than the 
apparently much higher affinities reported using trimeric ligand as analyte (a reflection of the 
effects of avidity and measurements of an apparent Kd).  Indeed, the issue or measuring single-
site affinities versus apparent affinities of oligomeric interactions plagues the TNFSF literature.  
Table 1.2 outlines the reported binding affinities of RANKL for RANK and OPG, as well as the 
affinity of TRAIL for OPG.  Within the RANK/RANKL interaction alone, the affinities vary 
from 2.0 uM to 68 pM.  This nearly 30,000-fold difference in affinity could be explained by 
experimental design alone, as the extraordinarily high affinity measurement reflects SPR-
determination by immobilizing monomeric ligand and flowing over trimeric ligand as the 
analyte.  Variation in other measurements could be due to different purification systems yielding 
glycosylated or non-glycosylated versions, or due to differences between murine and human 
variants.  Ultimately, single-site affinity measurements by SPR are substantially more 
quantitative and therefore all binding data presented in this dissertation will reflect this type of 
analysis.   
 
Signaling downstream of RANKL binding to RANK  
Despite its long cytoplasmic tail, RANK receptor possesses no intrinsic enzymatic 
activity and instead recruits signaling adaptors via conserved motifs, including TNF-receptor 
associated factors (TRAFs).  Indeed, recruitment (48) and subsequent ubiquitin ligase activity 
(55) of TRAF6 is required for osteoclast differentiation.  Following activation of TRAF6, TAB2 
and TAK1 are recruited (56, 57) which allows for the ubiquitination and activation of IKKg or 
NEMO (58).  Eventually, active IKK complex phosphorylates the NF- B repressor I Ba, 
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leading to its proteasomal degradation and allowing NF- B to translocate to the nucleus (59) 
where it regulates the expression of several osteoclast-specific genes.  Additionally, during 
differentiation RANK signaling via TRAF6 can activate the MAP kinases p38, JNK, and ERK 
(60).  Together, these kinases activate the transcription factors c-fos and c-Jun, which can act in 
concert to promote the upregulation of several crucial genes, including NFATc1 (61).  The 
crucial step of NFATc1 activation (62) by RANK signaling occurs in conjunction with co-
stimulatory ITAM signals (63) acting via PLCgamma2 and calcium signaling (64).  In addition 
to TRAF-binding motifs, other regions of the RANK cytoplasmic motif have been implicated in 
its signaling.  Several groups have pointed to a crucial “IVVY” motif as being important for 
osteoclastogenic signals (65, 66), perhaps through the recruitment of PLCgamma2 and the 
scaffold protein Gab2 (67). 
 RANK signaling not only induces differentiation of macrophages into osteoclasts, it can 
also activate the mature cell to resorb bone (68).  In mature cells, this occurs via organization of 
the cytoskeleton to form actin rings (69).  The binding of TRAF6, but not other TRAFs, is 
essential for proper cytoskeletal organization (70).  Indeed, mice lacking a molecule that serves 
to negatively regulate the association of TRAF6 and RANK exhibit not only enhanced 
osteoclastogenesis, but also enhanced activation of the cytoskeleton in response to RANKL 
treatment (71).  RANKL mediated actin ring formation is also dependent upon Src kinase 
activity (72, 73) and the ability to induce Src-mediated formation of a cytoskeletal organizing 
RANK/Src/avB3 complex (74).   
 
Initiating Signal Transduction  
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Although the signaling cascades described above have been extensively characterized, 
the precise mechanism that transforms extracellular ligand binding into intracellular, receptor-
initiated signaling cascades remains a fascinating question. For G-protein coupled receptors 
(GPCRs), ligand binding is thought to induce a conformational change that recruits 
heterotrimeric G-proteins and promotes the exchange of GDP for GTP, thus initiating signaling 
(75).  The classic example of oligomeric ligand causing receptor activation is in the epidermal 
growth factor receptor (EGFR).  At resting state, monomeric and dimeric receptor species are in 
equilibrium but ligation by dimeric EGF stabilizes the oligomer, promoting its intrinsic kinase 
activity and inducing autophosphorylation/activation (76).  No known TNF receptor contains 
instrinsic enzymatic activity or directly recruits an intracellular enzyme.  It has been largely 
assumed that ligand-induced trimerization of individual monomer receptor chains is the initiating 
event for signal transduction.  For some TNF receptor members, it has been proposed that 
multimers of receptor are pre-formed in the absence of ligand (77-80), and that ligand binding 
allows for a conformational change that brings the intracellular adapter-recruitment motifs into 
proximity (81).  Although there exists a crystal structure of TNFR1 in a dimeric state with 
extensive contacts form at the proposed “pre-ligand association domain” (47), the crystal 
structures of several TRAFs alone or bound to the receptor pepties site show formation of a 
trimeric species (82).  Therefore, the exact oligomeric nature of receptor required for the 
initiating of downstream signaling remains to be fully elucidated.  More recently, higher order 
clustering has been proposed for several TNFRs (83-85). 
 Several studies have attempted to address the issue of receptor oligomerization necessary 
for RANK signal initiation.  In one study, a chimeric protein consisting of RANK cytoplasmic 
domain fused to the erythropoietin extracellular portion was transfected into the immortalized 
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macrohpage cell line RAW264.7 (86).  Agonist antibody ligation purportedly results in dimeric 
clustering of receptor, and in this context the authors observed decreased osteoclast formation 
and function.  However, a separate group reported that the overexpression of differentially 
tagged RANK receptor could lead to its ligand-independent clustering and activation (87).  This 
group identified the same IVVY cytoplasmic motif described above as recruiting Gab2 and 
PLCg as being responsible for pre-ligand receptor association.  However, careful titration of 
RANK in a subsequent overexpression study (88) failed to reproduce ligand-independent 
receptor clustering and signal transduction, highlighting the need for tools to address this 
fundamental issue using unmanipulated, primary cells. 
 
Single-chain TNFSF   
The ligands of the TNFSF fold in such a way that the N- and C-termini of neighboring 
monomers are immediately adjacent.  This fact has been used by several groups to create 
versions of TNFa (89) or TRAIL (90, 91) that contain each monomer covalently linked by short, 
flexible amino acid stretches.  These constructs have been termed “single-chain” because the 
trimeric ligand is synthesized as one, single polypeptide chain.  Additionally, Boschert et al (92) 
demonstrated that in principle it is possible to individually mutate the receptor recruitment sites 
within single-chain TNF.  Although they used these constructs to probe the differences in 
TNFR1-Fas or TNFR2-Fas chimeric receptor overexpressing cell lines, it is easy to conceive a 
scenario where these proteins could be used to address issues of receptor multimerization in 
unmanipulated cells using TNFR1 or TNFR2 selective variants. 
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1.2 Rationale for the thesis   
We reasoned that construction of a single-chain RANKL (scRANKL) would allow us to 
probe the receptor oligomeric state of RANK necessary and sufficient for downstream signaling 
in osteoclast precursors.  To this end, we constructed and optimized the expression of scRANKL.  
We utilized our previously described co-crystal structures to generate mutations in RANKL 
incapable of recruiting RANK receptor and introduced this mutation into scRANKL.  
Additionally, we reasoned that we could identify a version of scRANKL capable of binding 
RANK receptor yet incapable of generating osteoclastogenic signals thus providing a novel 
mechanism for inhibition.  Not surprisingly, scRANKL variants incapable of binding receptor at 
one or two sites were unable to compete with the avidity afforded to trimeric, WT-RANKL.  An 
additional aim of this work was to identify mutations in RANKL that increased the affinity for 
RANK.  Upon insertion into the intact receptor recruitment sites, we were able to generate a 
highly effective RANKL inhibitor.  We tested this ability of this protein to antagonize RANKL-
mediated osteoclast formation both in vitro and in vivo.   
 From our attempts to identify high affinity RANKL, we generated a panel of mutants 
with a wide range of affinities for RANK.  We observed that there was not a simple linear 
relationship between receptor binding and osteoclastogenic capacity.  Rather, supraphysiologic 
binding mediated by extremely long off-rates is not equally capable of agonist activity as 
variants with only modest increases in affinity.  This biphasic effect suggests a mechanism for 
receptor activation that relies on the ability not only to associate, but also to dissociate from 
receptor, as being crucial for activation.   
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1.3  Tables 
 
 
 
 
 
Table 1.1  RANK, OPG, and RANKL mutations at the ligand/receptor interface 
 Mutation 
(Human) 
Residue 
(Murine) 
Location in 
structure 
Structural predictions Disease Association Reference 
OPG C44R C23 CRD1  Disulfide bond to C62 disrupted -> 
improper folding 
Idiopathic 
hyperphosphatasia 
(juvenile Paget’s 
disease) 
(54) 
C65R C44 CRD2 – A1 Disulfide bond to C87 disrupted -> 
improper folding 
Idiopathic 
hyperphosphatasia 
(juvenile Paget’s 
disease) 
(31) 
C87Y C66 CRD2 – B2 Disulfide to C113 disrupted -> 
improper folding 
Idiopathic 
hyperphosphatasia 
(juvenile Paget’s 
disease) 
(31) 
F117L F96L CRD3 – A1 Loss of crucial hydrophobic and 
aromatic ring stacking energetics -
> decreased affinity for RANKL 
Idiopathic 
hyperphosphatasia 
(juvenile Paget’s 
disease) 
(31) 
ΔD182 (in 
frame) 
D161 CRD4 – B1 Equivalent RANK residue 
involved in intramolecular salt 
bridge to conserved T174, loss of 
salt bridge could lead to protein 
instability.  Alternatively, this may 
displace nearby C195 needed for 
disulfide bond to C175 
Idiopathic 
hyperphosphatasia 
(juvenile Paget’s 
disease) 
(93) 
  
RANK G53R G24 CRD1 – B2 Needed to make a tight turn. 
Probably disrupts folding of CRD1 
ARO (94) 
R129C R100 CRD3 A->B X2 Salt bridge to RANKLE225, 
hydrogen bonds to RANKLN266, 
E268 disrupted interactions -> 
decreased affinity  
ARO (Compound 
heterozygote with 
C175R) 
(94) 
A134V A105 CRD3 – B1 Adjacent to C104, may disrupt 
disulfide bond to C151 
ARO (95) 
D148V D119 CRD3 – B1 Intramolecular salt bridge to 
mainchain T102 and His90, may 
be important for folding or stability 
ARO (95) 
R170G K141 CRD4 A->B X2 Forms intramolecular salt bridge to 
D162 which may be important for 
folding or stability 
ARO (94) 
C175R C146 CRD4 – B1 Disulfide to C195 disrupted -> 
improper folding 
ARO (Compound 
heterozygote with 
R129C) 
(94) 
      
  
RANKL Δ145-177 146-176 A strand into 
AA’ loop 
Important contacts to RANK, 
likely impact binding.  Not heavily 
contacted by OPG. 
ARO (96) 
M199K M198 A’’-B’ loop No contacts to RANK or OPG, no 
inter-monomer RANKL contacts.   
Core residue that may be important 
for monomer folding. 
ARO (96) 
Frameshift 
at V277 
V276 F strand Missing F, G, and H strands likely 
critical for proper folding or trimer 
assembly 
ARO (96) 
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*Indicates isothermal calorimetry (ITC) experiment with TNFSF member injected into a stirred 
cell of TNFRSF member.  All other experiments were performed using surface plasmon 
resonance (SPR). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.2. Reported murine or human RANK/RANKL, OPG/RANKL or OPG/TRAIL 
binding affinities. 
Immobilized Analyte ka (1/Ms) kd (1/s) KD (M)   Reference 
mRANKL mRANK (CRDs) 4.7 x 10
4
 1.1 x 10
-1
 2.6 x 10
-6
 (34) 
mRANK mRANKL NR NR 6.8 x 10
-11
 (35) 
mRANK* mRANKL* NR NR 2.3 x 10
-7
 (36) 
hRANK hRANKL NR NR 2.1 x 10
-9
 (97) 
hRANK hRANKL NR NR 1.1 x 10
-10
 (98) 
RANK-Fc RANKL 4.9 x 10
5
 3.3 x 10
-4
 6.7 x 10
-10
 (99) 
 
mRANKL mOPG (CRDs) 1.4 x 10
6
 1.1 x 10
-3
 5.1 x 10
-9
 (34) 
hRANKL hOPG (CRDs) 6.5 x 10
6
 4.2 x 10
-3
   6.5 x 10
-10
 (38) 
hOPG-Fc hRANKL 7.6 x 10
5
 1.3 x 10
-3
 1.7 x 10
-9
 (50) 
hRANKL hOPG (FL) 3.0 x 10
5
 2.0 x 10
-3
 1.0 x 10
-8
 (50) 
hRANKL hOPG (CRDs) 1.6 x 10
3
 5.0 x 10
-3
 3.0 x 10
-6
 (50) 
hOPG-Fc hRANKL NR NR 6.7 x 10
-9
 (100) 
 
  
hOPG-Fc hTRAIL NR NR 4.5 x 10
-8
 (101) 
hOPG-Fc hTRAIL NR NR 4.0 x 10
-7
 (43) 
hOPG-Fc hTRAIL NR NR 1.0 x 10
-9
 (102) 
hOPG-Fc hTRAIL 6.6 x 10
4
 2.0 x 10
-4
 3.0 x 10
-9
 (44) 
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Chapter 2 
Manipulation of Receptor Oligomerization as a Novel Strategy for TNF 
Superfamily Inhibition  
 
Portions of this chapter are adapted from the manuscript submitted to Science for consideration, 
November, 2013. 
 
Julia T. Warren, Christopher A. Nelson, Corinne E. Decker, Daved H. Fremont, Steven L. 
Teitelbaum 
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2.1 Abstract 
Receptor activator of NF-kB ligand (RANKL) is the key cytokine regulating osteoclast 
formation and is therefore a therapeutic target for treatment of disorders such as osteoporosis and 
skeletal metastasis.   The molecular details initiating osteoclastogenesis and thus bone resorption, 
particularly the state of RANKL receptor (RANK) oligomerization, are unclear.  We describe a 
novel RANKL construct, with all three monomers covalently linked as a single polypeptide 
chain, which enables delineation of the receptor oligomeric state necessary and sufficient to form 
bone resorptive cells. We find RANKL-induced trimeric clustering of its receptor, RANK, to be 
a prerequisite for optimal osteoclast formation, although dimeric clustering is also capable of less 
efficiently generating the cell.  We used this information to modify the affinity of individual 
single-chain RANKL monomers for RANK as well as for the decoy receptor, osteoprotegerin 
(OPG). This approach yielded an effective inhibitor of osteoclastogenesis, in vitro and in vivo, 
thus providing a novel strategy for anti- resorptive therapy. As RANKL is a member of the 
tumor necrosis factor superfamily (TNFSF), our observations may also inform the design of 
inhibitors for other TNFSF members.   
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2.2 Introduction 
The TNFSF and its associated receptors represent a protein family with wide-ranging 
roles in physiology and homeostasis (1).  Excess activation of TNF superfamily (TNFSF) 
receptors induces a myriad of pathological conditions such as psoriasis, inflammatory joint 
disease and osteoporosis (2, 3). While biological agents such as humanized monoclonal 
antibodies and decoy receptors have positively impacted the course of these diseases, each has 
limitations including acquired resistance, predisposition to infectious diseases and malignancy as 
well as marked suppression of skeletal remodeling (4).  The TNFSF member RANKL is the key 
cytokine regulating osteoclast formation and function (5, 6) and excess activation of its receptor, 
RANK, promotes pathological bone loss (7).  RANKL exists as a homotrimer in solution (8) 
with each of the three interfaces separating the monomers containing a binding groove that can 
accept a single copy of RANK or the anti-osteoclastogenic decoy receptor, OPG (9-11).   
Despite the trimeric nature of the cytokine, the assumption that osteoclastic signaling is 
initiated by clustering of three RANK monomers is controversial.  This largely reflects the fact 
that previous studies have relied on the overexpression of RANK or of various 
RANK/extracellular receptor chimeras. Enforced dimerization of RANK by overexpression of a 
RANK cytoplasmic domain fused to the extracellular portion of the Epo receptor and ligation of 
this chimera with anti-Epo antibody led to decreased osteoclast formation (12).  However, this 
study, and a subsequent publication using a RANK overexpression system (13), show that even 
in the absence of RANKL, TRAP-positive osteoclasts can be observed.  The relevance of this 
ligand-independent RANK functionality is uncertain, as mice and humans lacking functional 
RANKL fail to form osteoclasts (5, 6, 14).  Additionally, the careful selection of stable cell lines 
expressing similar levels of RANK as found in osteoclast precursors did not lead to ligand-
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independent signaling (1, 15).  Together, these studies highlight the need for tools to examine 
these fundamental questions in the context of primary, unmanipulated cells. 
 Indeed, the receptor oligomeric state necessary and sufficient for signaling has been an 
area of interest more broadly within the TNF superfamily.  For some TNF receptor members, it 
has been proposed that multimers of receptor are pre-formed in the absence of ligand (2, 3, 16-
19), and that ligand binding allows for a conformational change that brings the intracellular 
adapter-recruitment motifs into proximity (4, 20).  Similar to RANK overexpression, ligand-
independent TNFR1-mediated apoptosis actually prevents generation of cells overexpressing this 
receptor (5, 6, 21).  Although there exists a crystal structure of TNFR1 in a dimeric state with 
extensive contacts formed at the proposed “pre-ligand association domain” (7, 22), the crystal 
structures of several TRAFs alone or bound to receptor fragments show formation of a trimeric 
species (8, 23).  Therefore, the exact oligomeric nature of receptor required for the initiating of 
downstream signaling remains to be fully elucidated.   
 Recently, several groups have described the use of "single-chain" protein variants within 
the TNFSF containing each monomer covalently linked by short, flexible amino acid stretches 
(9-11, 24-26). This is possible because the ligands of the TNFSF fold such that the N- and C-
termini of neighboring monomers are in close physical proximity.  Indeed, a single-chain version 
of TNF  with individually mutated receptor recruitment sites was generated and used to show 
that TNFR1 needs only one available recruitment site to promote cell death of a TNFR1 
extracellular / Fas intracellular chimeric receptor (12, 27).  Though the authors propose a 
mechanism whereby pre-associated TNFR1 dimers become signaling competent via the binding 
of two separate TNF homotrimers to each TNFR1 dimer, their surprising finding may be 
confounded by the chimeric and overexpressed nature of the receptor. 
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 In the present study, we created a single-chain version of RANKL (scRANKL) by 
covalently linking each monomer with flexible glycine-serine repeats.  We designed mutations to 
prevent RANK receptor recruitment and introduced them individually into each scRANKL 
monomer, generating versions capable of recruiting only two or one RANK monomer to each 
scRANKL.  Our examination of these scRANKL variants using primary, bone marrow 
macrophages with endogenous levels of RANK receptor allow us to comment on the receptor 
oligomeric state necessary and sufficient for downstream signaling and osteoclast formation.  
Additionally, we used a non-biased, forward genetic approach to delineate RANKL variants with 
high affinity for RANK and decreased binding to the decoy receptor osteoprotegerin (OPG).  
Insertion of these novel RANKL mutants into the intact receptor recruitment sites of single- or 
double-block scRANKL generated an effective inhibitor of WT RANKL-mediated osteoclast 
formation and function.  This combined strategy of single-chain trimers with high affinity intact 
sites may be broadly applicable to other TNF receptor signaling systems. 
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2.3 Materials and Methods:  
Construction of single-chain RANKL vector: Initially, scRANKL was cloned into the 
pGEX vector (GE-Healthcare) by PCR amplification of mouse RANKL monomer (residues 
162–316 of NCBI Reference Sequence NP_035743) using primer pairs that yielded the 
following restriction sites: 5’ SmaI-RANKL-3’BspEI, 5’BspEI-RANKL-3’BamHI, 5’BamHI-
RANKL-3’NotI.  The primers were designed such that the three monomers are separated by a 
linker sequence ([Gly-Gly-Ser-Gly] x 3). Each insert was double-digested with the appropriate 
restriction enzymes (Fermentas) and ligated into the pGEX vector between the SmaI and NotI 
sites.  The entire scRANKL gene was subcloned into a mammalian protein expression vector 
(pFM (13, 28), gift of Dr. Filipo Mancia) downstream of the signal peptide from pHLsec 
(MGILPSPGMPALLSLVSLLSVLLMGCVA) (5, 6, 14, 29).  To aid protein recovery a TEV 
protease cleavage site and 6-histidine tag were added at the c-terminus 
(SSGRENLYFQGHHHHHH).  In brief, the construct encodes: a signal-peptide, RANKL (aa 
162-316) linker- RANKL (aa 162-316) linker - RANKL (aa 162-316) - TEV cleavage site - 
6xHis.  Expression is driven by the CMV promoter. Transfection efficiency is monitored as red 
fluorescent protein production, which initiates downstream of scRANKL at an internal ribosomal 
entry site. 
Production of mammalian RANKL protein:  Suspension adapted 293-Freestyle cells 
(Life Technologies) were maintained in serum-free Freestyle 293 expression medium (Life 
Technologies) according to the manufacturer’s protocol.  For transfection of RANKL variants, 
DNA was prepared using an endotoxin-free maxiprep kit (Qiagen).  Cells were seeded at a 
density of 0.5x10
6
/mL in 200mL volume 24 hours prior to transfection.  On the day of 
transfection, DNA and polyethylenimine (29)were mixed at a ratio of 1:3 (WT RANKL or triple-
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chain variants, 200ug:600ug) or 1:2 (single-chain RANKL variants, 200ug:400ug) in opti-
mem(Life Technologies), incubated for 15 minutes at room temperature, and added directly to 
cells.  Supernatant was harvested four and seven days after transfection, 0.22uM filtered and 
equilibrated by the addition of 1/10 volume 10X phosphate buffered saline (Gibco) and 10mM 
imidazole.  The protein was captured on Ni-NTA Superflow resin (Qiagen) and washed using 
10mM imidazole in PBS.  Protein was eluted in steps from 25-500mM imidazole.  Fractions 
containing purified protein were identified on coomassie stained SDS-PAGE.  Positive fractions 
were pooled and concentrated using a disposable YM30 centricon (Millipore). All proteins were 
sterile filtered for use in cell culture. 
Chemical cross-linking: Purified WT-RANKL (500ng) was incubated with varying 
concentrations (0-500uM) of the chemical cross-linker bis-(sulfosuccinimidyl)-suberate (BS
3
, 
Pierce) in PBS at room temperature for 30 minutes, at which time the reaction was stopped by 
the addition of 10mM Tris-HCl, pH=7.0.  Samples were boiled in reducing conditions and 
loaded onto SDS-PAGE gels (10%) alongside 500ng of scRANKL protein.  Bands were stained 
using the coomassie derivative Imperial protein stain (Pierce) and visualized using the Odyssey 
scanner (Licor). 
Multi-angle light scattering (MALS): Purified RANKL proteins were applied to a 
Wyatt WTC-030S5 size exclusion column mounted on a Waters HPLC system attached to a 
multi-angle light scattering device. The light detectors, a Dawn HELEOS-II 18-angle light 
scattering detector, and an Optilab rEX refractive index, were previously calibrated against 
monomeric bovine serum album. MALS was monitored during the experiments and the resulting 
data analyzed using associated software. For each experiment, 250 ug of sample was applied at 1 
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mg/ml in running buffer (25mM HEPES pH 7.4, 150 mM NaCL, 0.01% sodium azide) at 20°C 
and a flow rate of 0.5 ml per minute. 
Identification of RANKL mutants which do not bind RANK. RANKL residues 
forming salt bridges or hydrogen bonds with RANK were targeted for site directed mutagenesis 
using the program PISA and the RANK/RANKL co-crystal structure (9). Loops at the 
RANK/RANKL interface were disrupted by amino acid insertion. Mutations were introduced 
into the expression construct, pGEX- GST-RANKL, by PCR using Phusion polymerase (NEB). 
After verification by nucleic acid sequencing, the mutant RANKL-encoding constructs were 
transformed into E. coli  strain BL21-CodonPlus (DE3)-RIL competent cells (Agilent 
Technologies) for protein production. Correctly-folded soluble protein was purified from cell 
lysate on glutathione sepharose (8). 
Bio-layer interferometry (BLI):  All BLI experiments were performed on an Octet RED 
system (ForteBio).  GST-RANKL proteins were biotinylated using NHS-PEG4-biotin (Pierce) 
according to manufacturer’s protocol, and excess biotin was removed by desalting over Zeba 
Spin Columns (7KD molecular weight cutoff, Pierce).  Biotinylated proteins were adsorbed onto 
super-streptavidin sensor pins (ForteBio).  Binding of RANK-Fc or OPG-Fc was measured in 
HBS-EP containing 1% BSA.  Due to the dimeric nature of Fc-tagged receptors, only apparent 
Kd values were observed.  
Surface Plasmon Resonance (SPR):  All SPR experiments were performed on a Biacore 
T-100 (GE Healthcare) using CM5 sensor chips and HBS-EP buffer.  To confirm receptor 
recruitment using scRANKL variants, 4,000 RU of WT-scRANKL or variant scRANKL were 
coupled to individual lanes, leaving one reference flow cell uncoupled.  Monomeric RANK 
(20uM) was flowed over until saturation.  Total RUs bound at equilibrium were calculated using 
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BIAEvaluation software.  Experiments to determine kinetic affinity constants of RANKL 
variants for RANK or OPG were performed and analyzed as previously described (9). 
Generation of osteoclasts from primary bone marrow macrophages:  Long bones of 
eight week-old mice were flushed and the marrow subjected to red blood cell lysis.  The 
remainder of the whole marrow was cultured on petri dishes maintained at 37°C with 6% CO2 in 
alpha-mem containing 10% inactivated fetal bovine serum, 100 U/ml penicillin, 100 μg/ml 
streptomycin, (α-10 medium) supplemented with 1:10 CMG (conditioned medium supernatant 
containing recombinant M-CSF) (30).  Osteoclasts were differentiated in α-10 medium with 1:50 
CMG and the relevant RANKL variant. 
Detection of osteoclast formation:  Cells were fixed in 4% paraformaldehyde in PBS 
for 15 minutes and stained for the tartrate resistant acid phosphatase (TRAP) using a kit (Sigma).  
Additionally, osteoclasts were quantified by a solution assay of TRAP enzyme levels.  Cells 
were fixed and lysed in 90mM citrate buffer pH=5.2, 80mM sodium tartrate, 0.1% Triton-X 100 
for 10 minutes at room temperature.  Colorimetric nitrophenylphosphate (substrate of TRAP 
enzyme) was added and visualized after 15 minutes by the addition of sodium hydroxide.  Data 
was acquired using the 405nM absorbance filter on a Bio-rad plate reader.  Because of the 
limited range of the TRAP solution assay, a more quantitative assessment of TRAP activity was 
performed using the fluorescent phosphatase substrate ELF-97 (Molecular Probes).  Fixed cells 
were incubated with 100uM ELF-97 in 90mM citrate buffer pH 4.8, 80mM sodium tartrate for 
15 minutes at room temperature.  The reaction was stopped by the addition of sodium hydroxide 
and fluorescence was visualized using the 345/530 excitation/emission filter on a Spectramax 
M2 plate reader.  
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Quantitative real-time PCR:  To quantitate mRNA markers of osteoclast formation, 
RNA was isolated from cultured cells according to the manufacturer’s protocol (Qiagen RNeasy 
miniprep kit).  Equal amounts of RNA were used to perform reverse transcription (Bio-rad 
iScript) and quantitative real-time PCR was performed using Eva Sso fast qPCR Sybr green kit 
(Bio-rad) using a 7500 fast machine (ABI).  Data was analyzed according to the delta-delta Ct 
method and normalized to a control containing no RANKL addition (labeled BMM).  Primers 
used were as follows: CatK (Forward: 5’-ATGTGGGTGTTCAAGTTTCTGC-3’, Reverse: 5’-
CCACAAGATTCTGGGGACTC-3’), NFATc1 (Forward: 5’-CCCGTCACATTCTGGTCCAT-
3’, Reverse: 5’-CAAGTAACCGTGTAGCTGCACAA-3’), TRAP (Forward: 5’-
CAGCTCCCTAGAAGATGGATTCAT-3’, Reverse: 5’GTCAGGAGTGGGAGCCATATG), 
beta3 (Forward: 5’-TTCGACTACGGCCAGATGATT-3’, Reverse: 5’-
GGAGAAAGACAGGTCCATCAAGT-3’). 
Western blot:  Cells were washed three times in ice-cold PBS and lysed with RIPA 
buffer (Millipore) supplemented with protease and phosphatase inhibitor cocktail (Pierce).  After 
10 minutes of incubation on ice, cell lysates were cleared of debris by pelleting for 15 minutes at 
21,000g.  40-50ug of protein were loaded onto SDS-PAGE gels (10%), transferred onto PVDF 
membrane, and incubated with primary antibody overnight.  After extensive washing and 
incubation with near-infrared labeled secondary antibody, membranes were visualized using the 
Odyssey scanner (Licor).  Primary antibodies to detect phosphorylated or total NF-kB or p38 
were from Cell Signaling, antibody directed against actin was from Sigma, and fluorescently 
labeled secondary antibodies were from Rockland. 
Yeast surface display of RANKL and staining with receptor:  WT-SM RANKL was 
cloned into the pYD1 yeast display vector (Life Technologies) using 5’ NheI and 3’ XhoI 
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restriction sites, yielding the yeast mating protein Aga2p fused to the RANKL N-terminus and 
having at the C-terminus a V5-epitope tag.  The pYD1-RANKL construct was transformed into 
EBY100 yeast as described and colonies selected in tryptophan-deficient, glucose-based media at 
30˚C.  Display of RANKL protein was induced by inoculating into galactose-based selective 
media and incubating at 30˚C with shaking for 24-48 hours.  Surface expression of RANKL was 
detecting using an anti-V5- FITC antibody (Invitrogen).  After incubation with RANK-Fc or 
OPG-Fc for 10 minutes at room temperature and washing with ice-cold PBS, receptor binding 
was detecting using an anti-human Fc-APC antibody (Molecular Probes).  All experiments were 
performed using LSR II or Canto II flow cytometers (BD Biosciences) and analyzed using the 
FlowJo software package (Tree Star, Inc.).  Alternatively, RANK-6xHis or OPG-6xHis were 
detected using APC-labeled anti-6xHis antibody (MBL International). 
Generation of RANKL library and selection: Primers annealing immediately 5’ or 3’ 
to RANKL in the pYD1 vector were designed and used in error-prone PCR amplification (Gene 
Morph II, Agilent).  A lower and higher mutation rate was accomplished by manipulating the 
amount of starting template and the number of amplification cycles.  The resulting product was 
further amplified using the high fidelity Phusion polymerase (Finnzymes).  Simultaneously, 
pYD1 vector backbone was amplified using primers that extended outward from the regions 
surrounding RANKL-V5, leaving 24 base pairs of overlap between the vector backbone and the 
amplified, mutant RANKL-V5 insert.  These purified PCR products were transformed into 
EBY100 cells according to established protocols (31), yielding a library of approximately 1x10
6
 
transformants.  Selections were made using magnetic assisted cell sorting (MACS, Miltenyi). 
Roughly 1x10
7
 cells were induced from either the low or high mutation rate libraries, and both 
were first sorted for the expression of the V5 C-terminal tag indicating proper folding and full-
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length protein.  This was performed by incubating cells with FITC-labeled anti-V5 antibody and 
selecting cells using anti-FITC mibrobeads for cell separation.  After growth of the selected 
clones, cells were again induced to display RANKL protein, incubated with OPG-Fc, washed, 
and clones that did not bind OPG were collected as the flow-through on a Protein A magnetic 
bead column.  These cells were then labeled with RANK-Fc, and this time those clones that 
retained binding to the Protein A column were collected.  After sorting, cells were expanded in 
selective media and this strategy repeated two additional times yielding clones termed “LM3S” 
and “HM3S”.  Roughly 200 individual colonies were isolated from the libraries and stained with 
OPG-Fc.  Those clones with little to no detectable staining were then assessed for their ability to 
bind RANK-Fc.  DNA was extracted from the top scoring clones of interest using a yeast 
miniprep kit (Zymoprep) and transformed into DH5alpha E. coli chemically competent cells 
(Invitrogen) for sequencing.  Individual point mutations were then added to RANKL using site-
directed mutagenesis, and subsequent combinations were cloned in a similar fashion.  A second 
round of error-prone PCR utilized the identical primers and protocol as above, but starting 
template of either F164Y/Q236H/F269Y or K194N/Q236H/F269Y triple mutants.  Clones were 
selected over three rounds of sorting using three sequentially lower amounts of monomeric 
RANK-6xHis and anti-6xHis microbeads.  Finally, the resulting library was incubated with 
RANK-6xHis at room temperature for 10 minutes and then tested for the ability to outcompete 
the presence of unlabeled OPG at room temperature for 5 minutes.  Residual RANK binding was 
detecting using APC-labeled anti-6xHis antibody.  In the course of sorting, K194E was identified 
and used to replace K194N, which introduced a potential N-linked glycosylation site at the 
interface with RANK or OPG. 
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Intraperitoneal RANKL Injection:  Balb/c 8-week old female mice were purchased 
from NIH Frederickson, housed in the animal facility at Washington University School of 
Medicine and maintained according to the guidelines set by the Association for Assessment and 
Accreditation of Laboratory Animal Care. All animal studies were approved by the Animal 
Studies Committee of Washington University School of Medicine.  PBS, WT-SM RANKL 
(0.5mg/kg), or WT-SM RANKL + single-block, RANK
high
 scRANKL (0.5mg/kg) were injected 
intraperitoneally at 0, 24, and 48 hours as described (32).  Mice were sacrificed 1.5 hours after 
the third injection and serum was collected by cardiac puncture.  CTx ELISA was performed 
according to the manufacturer’s protocol (Immunodiagnostics Systems). 
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2.4 Results 
To assess the oligomeric state of receptor clustering required for efficient initiation of 
signal transduction, we covalently linked three RANKL monomers by two short glycine-rich 
linkers (Figure 2.1). This single-chain version of trimeric RANKL (scRANKL) permits 
individual modification of RANK and OPG affinity at each of the three binding sites.  Two 
additional surface “solubility” mutations (C220S/E246I “WT-SM RANKL”), which do not 
impact RANK binding, were introduced to improve protein expression (Figure 2.2).  Whereas 
chemical cross-linking of wild-type homotrimeric RANKL (WT RANKL) is necessary to 
observe the trimer in a denaturing gel, scRANKL has a molecular weight consistent with three 
covalently-linked RANKL monomers (Figure 2.3A). Because the predominant scRANKL 
species migrates on the gel at a position slightly below chemically cross-linked trimeric RANKL, 
we calculated molecular weights using multi-angle light scattering (Figure 2.3B).  Importantly, 
scRANKL induces bone marrow macrophage (BMM)-derived osteoclastogenesis as effectively 
as WT (Figure 2.3C). 
To manipulate the number of individual RANK receptors recruited to scRANKL, we 
sought to identify mutations in RANKL incapable of binding RANK. To this end, we took 
advantage of the RANKL/RANK co-crystal structure detailing the key loops of the cytokine 
contacting its receptor.  We inserted short sequences into each RANKL loop as well as designing 
individual, salt bridge-disrupting, point mutations and quantitated apparent affinities for Fc-
tagged versions of the RANK or OPG cysteine-rich domain cytokine binding fragments (Figure 
2.4A).  One mutant of interest, with three amino acids (GGS) inserted into the CD-loop (CDins 
RANKL), fails to bind recombinant RANK-Fc despite proper folding established by its binding 
of OPG-Fc in a dose dependent manner (Figure 2.4A,B).  Indeed, all mutants with no detectable 
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binding to RANK-Fc contained mutations in this RANKL loop.  Interestingly, this same loop is 
the target for Denosumab, a humanized monoclonal antibody targeting RANKL and currently 
approved for the treatment of osteoporosis.   
Although we observe overall an excellent correlation between apparent affinity for 
RANK-Fc and capacity to generate osteoclasts as assessed by TRAP stain, TRAP solution assay, 
and osteoclastogenic mRNA markers (Figure 2.5A-C), it is noteworthy that several variants with 
no apparent biological activity still had detectable binding to RANK-Fc.  This is significant, as 
attempts to manipulate receptor oligomerization necessitate the complete absence of receptor 
recruitment.  This property is not readily detected by in vitro functional assays or measurements 
of affinity using the monomeric fragment of RANK which binds to WT RANKL with relatively 
low affinity (1uM).  Lastly, to confirm its failure to ligand RANK, we demonstrate that CDins 
RANKL is incapable of promoting RANK signaling (Figure 2.5D).   
Next, we generated single-block and double-block scRANKL by inserting CDins into one 
or two monomers, respectively (Figure 2.6A).  To demonstrate that we had selectively 
manipulated the number of receptors bound to the single chain protein, we coupled equal 
amounts of WT, single-block or double-block scRANKL, to individual lanes of a surface 
plasmon resonance (SPR) chip.   After flowing monomeric RANK, as an analyte, we measured 
the degree of receptor binding at saturation.  As expected, each monomer block results in the loss 
of approximately one-third of the receptor binding (Figure 2.6B).   
To test the hypothesis that recruitment of three RANK receptors is necessary to initiate 
osteoclastogenesis, we added the scRANKL variants to cultures of BMMs. Whereas WT-
scRANKL increases osteoclast number in a saturable, dose-dependent manner, triple-block 
scRANKL, containing CDins mutation in all three monomers, fails to generate any osteoclasts 
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(Figure 2.6C).  Double-block scRANKL also yields no osteoclasts, establishing that more than 
one RANK monomer is required. Surprisingly, however, single-block scRANKL is capable of 
generating osteoclasts although less effectively than WT.  This phenomenon is dose-dependent 
and saturable, maximizing at approximately 85% of control (Figure 2.6D). Mirroring 
osteoclastogenesis, single-block, but not double- or triple-block, scRANKL phosphorylates the 
effector molecules NF-kB and p38 (Figure 2.6E).  To confirm that this unexpected observation 
was not due to higher order clustering by aggregated protein, we further purified single-block 
scRANKL to more stringent molecular weight homogeneity.  We still observe osteoclast 
formation, albeit at lower levels (not shown).  Therefore, recruitment of two RANK receptors is 
sufficient and necessary to initiate osteoclast-forming signals, although it is less efficient than 
recruitment of three receptors.  
The capacity of double-block scRANKL to bind RANK, yet not produce osteoclasts, 
suggests it may function as a competitive antagonist of WT-RANKL.  To test this possibility, we 
induced osteoclast formation using WT RANKL and added increasing amounts of single- or 
double-block scRANKL, or OPG, a known inhibitor of osteoclastogenesis.  While OPG dose-
dependently inhibits osteoclast formation, neither version of scRANKL was able to antagonize 
this process (Figure 2.7).  This lack of inhibitory effectiveness likely reflects failure of the one or 
two intact binding site(s) to overcome the avidity afforded by the three sites of WT RANKL. We 
reasoned that we might generate effective inhibitors by compensating for the reduced avidity of 
single- or double-block scRANKL through increasing the affinity for RANK at the intact site(s). 
 This required identifying presently unknown RANKL mutations which increase RANK 
affinity.  To this end, we performed two generations of in vitro evolution through yeast surface 
display (YSD) (33).  The first generation involved creating a library of RANKL mutants using 
43 
 
error-prone PCR and sorting for clones that retain binding to RANK-Fc. Notably, OPG, the 
principal biological inhibitor of RANK-induced osteoclastogenesis (34-36), exerts its effects by 
competing for RANKL.  Because both RANK and OPG bind the same groove, it is possible that 
increasing the affinity of RANKL for RANK would simultaneously increase binding to the 
decoy receptor.  To obviate this possibility, we simultaneously sorted the library for clones 
recognizing RANK with high affinity and with decreased capacity to bind OPG-Fc and identified 
five clones of interest (Figure 2.8A).  Reversion mutagenesis yielded RANKL individual point 
mutations (K194E, Q236H, F269Y) which, when expressed in combination (KQF), substantially 
increase RANK-Fc and decrease OPG-Fc binding (Figure 2.8B-D).  
The goal of the second generation of evolution was to select RANKL variants with long 
RANK kinetic half-lives while still not recognizing OPG. We again constructed a RANKL 
mutant library using error-prone PCR, this time using high affinity KQF RANKL as a starting 
template.  Due to the rapid off-rate, monomeric RANK does not stain yeast-displayed WT-
RANKL, despite their established interaction.  We therefore sorted the second library using 
sequentially limiting amounts of monomeric RANK.  Staining at each stage of sorting 
demonstrated the emergence of a population now capable of binding monomeric RANK (Figure 
9A).   
Next, we selected RANKL variants which continue to bind limiting amounts of RANK 
after five minutes at room temperature, in the presence of unlabeled OPG (Figure 2.9B). 
Together, these strategies yielded an additional RANKL point mutant (H270Y) that further 
increases RANK recognition without detectable binding to OPG (Figure 2.9C,D).  We then 
determined the affinities and kinetic parameters of an intermediate and a high RANK binding 
variant by SPR.  Interestingly, although the two solubility mutations, introduced for production 
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of scRANKL, have no effect on RANK recognition, they induce an approximately ten-fold 
decrease in OPG binding (Figure 2.10).  Another point mutant, Q236H, yields a further 100-fold 
decrease in OPG and a roughly 15-fold increase in RANK binding as compared to WT RANKL 
(Figure 2.11A,B). Finally, KQFH recognizes RANK with approximately 500-fold greater 
affinity than does WT RANKL while failing to meaningfully bind OPG (Figure 2.11C). These 
alterations in affinity largely reflect a prolonged half-life, changing from relatively rapid 
dissociation time (WT-SM RANKL t1/2=3 seconds) to a value more than 200-times longer 
(KQFH-SM RANKL t1/2=675 seconds).    
We next used our mutational analysis to generate scRANKL constructs in which RANK 
and OPG recognition is blocked by a combination of CDins and Q236H as confirmed by yeast 
surface display (Figure 12A) and failure to form osteoclasts or induce signaling (Figure 
2.12B,C). To enhance RANK binding at the intact site(s), we used either intermediate (Q236H) 
or high affinity (KQFH) mutations, neither of which meaningfully recognize OPG, and generated 
all possible version of single- or double-block scRANKL.  All versions of double-block 
scRANKL remain incapable of generating osteoclasts (Figure 2.13A).  Furthermore, the 
decreased osteoclast formation and associated signals induced by single-block scRANKL 
variants reflect an inverse relationship with RANK affinity of the intact binding sites (Figure 
2.13B-D).  Because the RANK
med
  and RANK
high
 differ primarily in RANK off-rate (Figure 
2.11), our data suggest that the ability to dissociate from the receptor is crucial for initiating 
signal transduction in the face of sub-optimal receptor clustering.   
In contrast to the failure of single or double-block scRANKL containing unaltered 
residual monomer(s) to blunt RANK signaling and osteoclast formation, double-block, 
RANK
high
 scRANKL effectively inhibits with an IC50 approximating 10 nM (Figure 2.13E).   
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When two sites are available to bind RANK with high affinity (single-block, RANK
high
), the 
potency increases to an IC50 of 0.2 nM.  Lastly, we sought to test the effectiveness of single-
block, RANK
high
 scRANKL at blocking WT-RANKL induced osteoclastic bone resorption in 
vivo.  Intraperitoneal injection of WT-SM RANKL into 8-week old BALB/c mice increases 
osteoclast function as determined by the serum marker CTx (Figure 2.13F).  Suggesting 
therapeutic relevance of our observations, this increase in bone resorption is completely 
abrogated by an equal amount of single-block, RANK
high
.  
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2.5 Discussion 
The oligomeric state of cytokines often leads to the assumption of an identical oligomeric 
receptor clustering as the driving force for initiating signal transduction.  Our use of scRANKL 
with individually mutated receptor binding sites has allowed us to examine this assumption in 
unmanipulated primary cells.  Despite the trimeric nature of RANKL cytokine, the recruitment 
of only two RANK receptors is sufficient to generate osteoclasts.  The decreased 
osteoclastogenic capacity of single-block scRANKL indicates that this state of receptor 
clustering is, however, sub-optimal.  This data mirrors the observations made using an 
Epo/RANK chimeric receptor clustered by agonistic antibody treatment (12).  It is also 
reminiscent of an observed drop in the EC50 using single-chain TNF that blocks recruitment of 
one TNFR2/Fas chimeric receptor (27).  Although our observations are strengthened by the use 
of primary, unmanipulated cells that avoid the confounding factors of receptor overexpression, 
we cannot eliminate the possibility that the flexibility within our scRANKL linkers may allow 
for higher order multimerization of ligand and thus recruitment of additional RANK receptors in 
the context of single-block scRANKL.  Regardless, our data using double-block scRANKL, 
which is incapable of generating osteoclasts and inducing signals, stands in contrast to the 
observation that single-chain TNF blocking recruitment of two TNFR1/Fas chimeric receptors is 
equally capable of inducing cell death as WT TNF.  There are several possibilities for this 
difference, including the absence of overexpression in our system, the lack of compelling 
evidence for RANK pre-ligand association, or the recruitment of different intracellular signaling 
components.   
Interestingly, an increase in affinity at the two receptor recruitment sites in single-block 
scRANKL generates fewer osteoclasts.  As the primary difference in kinetics between WT-
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RANKL and our high affinity variants lies in the off-rate, it appears that the ability of single-
block scRANKL to generate osteoclasts may be facilitated by the rapid off rate at the two 
receptor binding sites.  This may allow for the recruitment of additional RANK receptor, 
ultimately leading to higher order clustering which has been implicated for other TNF receptor 
family members (37-42). Our data demonstrating that increasing the time required for single-
block scRANKL variants to dissociate diminishes osteoclastogenesis supports this model.   
Lastly, our observations establish that single-chain RANKL, in combination with blocked 
or high affinity RANK binding sites, allows arrest of RANK signaling, thus generating an 
effective inhibitor of RANKL-mediated osteoclast formation and function.  Indeed, single-block, 
RANK
high
 scRANKL inhibits osteoclast formation in vitro with an IC50 value of 0.2 nM, which is 
almost 10-fold lower than the reported IC50 value for Denosumab (IC50 = 1.64 nM), the anti-
human RANKL antibody approved for the treatment of osteoporosis (43).  RANKL, a member 
of the TNF superfamily (TNFSF), binds to multiple receptors (RANK and OPG) with different 
biological effects.  Within the TNFSF, there are several examples of cytokines demonstrating 
receptor promiscuity (44).  For example, TNFα, which recognizes TNFR1 and TNFR2, is central 
to the pathogenesis of disabling disorders such as rheumatoid arthritis and psoriasis (2). In fact, 
treatment of these diseases has been greatly facilitated by global TNFα blockade using 
humanized antibodies or soluble receptor (45). As effective as these drugs are, they carry major 
complications such as predisposition to malignancy and serious infections, including tuberculosis 
(46, 47). Current evidence indicates that the positive effects of anti-TNFa therapy reflects 
suppressed activation of TNFR1, while negative consequences are due to inhibition of the pro-
immune properties of TNFR2 (48). TNF and RANKL interact with their receptors in a 
homologous fashion (49). Our data demonstrate that the strategy of combining high affinity and 
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blocking mutations into a single-chain can be used to construct an effective inhibitor that is 
receptor selective.  This suggests a potential mechanism for blocking TNFR1 while sparing 
TNFR2, thereby reducing systemic complications.  Indeed, this strategy may be broadly 
applicable to all members of the pathologically important TNF superfamily. 
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2.7  Figure Legends 
Figure 2.1.  Construction and validation of single-chain RANKL.  WT-RANKL is depicted as 
three individual polypeptides (monomers), whereas WT single-chain RANKL (scRANKL) 
exists as a single polypeptide with [GGSG]x3 amino acid linkers. 
Figure 2.2.  Effect of solubility mutations on RANKL function.  Kinetic affinities for RANK of 
WT-RANKL or WT RANKL containing two solubility mutations (C220S/E246I, “WT-SM 
RANKL”) were determined using surface plasmon resonance (SPR).   
Figure 2.3. Characterization of scRANKL.  (A) Coomassie-stained SDS-PAGE gel of WT 
RANKL and scRANKL (500ng each) chemically cross-linked by increasing concentrations of 
BS3. (B) Multi-angle light scattering (MALS) of non-covalently linked RANKL or single-
chain RANKL.  Precise molecular weights of homotrimerically assembled RANKL (left) or 
single-chain RANKL (right) determined using MALS.  The differences in calculated and 
measured molecular weights reflect the presence of significant glycosylation on these 
mammalian cell-produced, secreted proteins. (C) Osteoclasts were generated from BMMs 
in the presence of recombinant WT RANKL or scRANKL and TRAP stained. 
Figure 2.4.  Design of RANKL mutants that prevent binding to RANK.  (A) Binding of 
RANKL variants to RANK-Fc or OPG-Fc as assessed by BLI.  Due to the dimeric nature of the 
analyte, KD values represent approximate affinity constants.  (B)  Representative BLI curves 
showing binding of WT-SM RANKL, CDins RANKL, or GST control to RANK-Fc or OPG-Fc.   
Figure 2.5. Functional characterization of RANKL mutants with varying degrees of RANK 
binding.  Osteoclastogenic capacity of recombinant RANKL variants in vitro assessed by (A) 
TRAP stain, (B) TRAP-solution assay and (C) osteoclastogenic marker mRNAs.  (D)  Signal 
transudction of WT-SM RANKL and CDins RANKL assessed by IκB phosphorylation.   
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Figure 2.6.  Degree of RANK monomer recruitment necessary and sufficient for 
osteoclastogenesis.  (A)  Individual monomer(s) of single- or double-block scRANKL are 
mutated to inhibit binding to RANK. Thus, single–blocked scRANKL contains two intact 
receptor recruitment sites and double- blocked, one. (B) Triplicate curves showing equal 
amounts of scRANKL variants coupled to an SPR chip with RANK as analyte.  The average 
number of RU for each binding curve at saturation is displayed.  (C)  Osteoclastogenesis 
induced by scRANKL variants assessed by TRAP activity.  (D)  EC50 values of osteoclast 
generation and percent maximum osteoclastogenesis relative to WT-scRANKL.  (E)  RANK-
mediated signaling induced by WT- and various sc-RANKL constructs (500ng/ml). 
Figure 2.7. Ability of single- or double-block scRANKL to inhibit osteoclastogenesis. (A) 
BMMs were cultured with WT-SM RANKL (200ng/mL) and increasing amounts of single- 
or double-block scRANKL. Four days later osteoclastogenesis was assessed by TRAP 
activity.  The addition of OPG monomeric fragment (4ug/mL) was used as positive control 
for inhibition of osteoclastogenesis.  (B) Representative TRAP stains of the highest 
scRANKL concentrations from part (A). 
Figure 2.8.  Reversion mutagenesis of YSD RANKL clones.  Binding to RANK-Fc (blue) or 
OPG-Fc (red) is expressed relative to WT-SM RANKL. (A) Top scoring clones from low 
(LM3S) or high (HM3S) mutation rate libraries with (B) individual point mutations of these 
clones.  (C) A second mutation was added to the most effective individual point mutant 
(Q236H). (D) A third mutation was added to closely approximate the ideal phenotype. 
Figure 2.9. Yeast-surface display generation of high affinity RANKL mutants.  (A)  Flow 
cytometry-based histogram showing staining with 1uM RANK at each phase of library 
sorting.  To select for clones with increased RANK binding, the three rounds of sorting were 
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initiated (Sort#1) with a concentration of RANKL 10-fold greater than the KD of RANK and 
was terminated (Sort#3) with a concentration 10-fold less. (C)  Kinetic and equilibrium 
affinities of WT-SM RANKL, SM RANKLQ236H, and SM RANKLKQFH were determined using 
SPR.  RANKL variants were coupled to a sensor chip and RANK or OPG monomeric 
fragments served as analyte. (B) Schematic representing competitive OPG YSD screen. In 
the context of wild-type RANKL (left side), RANK (purple) fused to 6-His is readily 
displaced by OPG (yellow) due to its higher affinity.  Alternatively, in the context of an 
increased affinity RANKL clone that has lost the capacity to bind decoy receptor, OPG is 
incapable of displacing RANK (right side).  Additionally, only those clones that have an 
increased half-life will have sustained binding after room temperature washing.  (C) 
Individual point-mutated RANKL clones retaining high RANK binding, detected by an anti-
6His mAb, after 5 minutes of OPG competition.  (B, C) Data are expressed as percent RANKL 
bound to RANK with time, relative to that bound in the absence of OPG. Additionally, 
binding of RANK (APC) is normalized to the level of RANKL yeast surface induction (FITC) 
expressed as the median fluorescence intensity (MFI) ratio (APC/FITC).  (D)   RANKL point 
mutants generated by YSD  KD values are estimated using titrating amounts of RANK 
binding to yeast surface-displayed RANKL and fitting median fluorescence intensity values 
to a one-site binding model.  ND = not enough data points to fit KD values, despite low levels 
of detectable staining at the highest concentrations.   
Figure 2.10. Effect of RANKL solubility mutations on OPG binding.  Kinetic affinities of WT-
RANKL or WT-SM RANKL were determined by SPR. 
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Figure 2.11. Kinetic parameters of RANKL high affinity variants.  Kinetic and equilibrium 
affinities of WT-SM RANKL (A), Q236H-SM RANKL (B), and KQFH-SM RANKL (C) were 
determined using SPR.  RANKL variants were coupled to a sensor chip and RANK or OPG 
monomeric fragments served as analyte. 
Figure 2.12.  Combined mutations of RANKL and OPG which block RANK binding. (A) 
Titration curves of RANKLCDins and RANKLCDins/Q236H binding to RANK or OPG assessed by 
flow cytometry of RANKL-displaying yeast cells.  Binding of RANK or OPG (APC) is 
normalized to the level of RANKL yeast surface induction (FITC) expressed as the median 
fluorescence intensity (MFI) ratio (APC/FITC). (B) Capacity of RANKLCDins and 
RANKLCDins/Q236H to generate osteoclasts in vitro. (C) Phosphorylation of IkB by RANKLCDins 
and RANKLCDins/Q236H (500ng/mL).   
Figure 2.13. Development of a competitive antagonist scRANKL.  (A) Induction of 
osteoclastogenesis, in vitro, by double-block scRANKL variants compared to WT scRANKL.  
(B)  Induction of osteoclastogenesis by double-block, RANK
high
 or single-block scRANKL 
variants with WT, medium or high RANK affinity at the intact binding sites quantitated by a 
fluorescent TRAP activity assay. (C) EC50 of osteoclast generation and percent maximum 
number of osteoclasts relative to WT-scRANKL.  (D) Capacity of increasing amounts of single-
block, RANK
high
 (orange squares) or double-block, RANK
high
 (orange triangles) scRANKL to 
inhibit  WT-SM RANKL-induced osteoclastogenesis.   WT-SM only (open diamond) serves as a 
positive control for osteoclast formation.  (E) Mice were injected with WT-SM RANKL +/- 
0.5mg/kg single-block, RANK
high
 scRANKL.  Two days later serum CTx was measured.  
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3.1 Abstract 
The interaction between Receptor Activator of NF-κB Ligand (RANKL) and its receptor RANK 
is essential for the differentiation and bone resorbing capacity of the osteoclast. Osteoprotegerin 
(OPG), a soluble homodimer, acts as a decoy receptor for RANKL and thus inhibits 
osteoclastogenesis. An imbalance in the RANKL/RANK/OPG axis, with decreased OPG and/or 
increased RANKL, is associated with diseases that favor bone loss, including osteoporosis.  
Recently, we established a yeast surface display system and screened libraries of randomly 
mutated RANKL proteins to identify mutations that abolish binding to OPG while preserving 
recognition of RANK. These efforts yielded several RANKL variants possessing substantially 
higher affinity for RANK compared to their wild-type (WT) counterpart.  Using recombinant 
RANKL mutant proteins, we find those with increased affinity for RANK produce more robust 
signaling in osteoclast lineage cells and have greater osteoclastogenic potential.  Our results are 
the first to document gain of function RANKL mutations. They indicate that the physiological 
RANKL/RANK interaction is not optimized for maximal signaling and function, perhaps 
reflecting the need to maintain receptor specificity within the tumor necrosis factor superfamily 
(TNFSF).  Instead, we find, a biphasic relationship exists between RANKL/RANK affinity and 
osteoclastogenic capacity.  In our panel of RANKL variants, this relationship is driven entirely 
by manipulation of the kinetic off-rate.  Our structure-based and yeast surface display-derived 
insights into manipulating this critical signaling axis may aid in the design of novel anti-
resorptive therapies as well as provide a paradigm for design of other receptor-specific TNF 
superfamily ligand variants. 
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3.2 Introduction 
The tumor necrosis factor superfamily (TNFSF) is composed of 19 different type II 
transmembrane ligands whose involvement in homeostasis and disease is wide-ranging (1).  
Many of these cytokines target or are produced by cells of the immune system, and participate in 
development and function of hematopoietic lineage cells (2-9).  TNFSF cytokines act by binding 
to and inducing signals downstream of TNF-receptor superfamily (TNFRSF) members (10, 11).  
Additionally, there are several examples within TNFRSF of decoy receptors whose binding can 
modulate the activity of these cytokines (12).  Due to their diverse roles in human disease, there 
are currently several therapies aimed at targeting these receptor/ligand pairs (13, 14).   
The control of skeletal mass is regulated in part by the bone resorptive osteoclast, whose 
differentiation and function rely on the TNFSF cytokine receptor activator of NF-kB ligand 
(RANKL) (15).  By interacting with its receptor RANK, RANKL induces signaling to NF-kB, 
MAP kinases, and NFATc1 among others (16, 17).  These crucial signaling events are blocked 
by osteoprotegerin (OPG), a secreted decoy receptor that binds RANKL and prevents its 
interaction with RANK (18, 19).  RANKL-mediated signaling promoting osteoclast formation 
and function, in excess of the bone anabolic osteoblast, is associated with many diseases 
including osteoporosis, inflammatory osteolysis, and skeletal metastasis (20).  Therefore, 
understanding the molecular events initiating signal transduction remains key to the development 
of future therapeutics targeting this signaling axis. 
Most TNFSF members exist as homotrimers in solution (21), and it is largely assumed 
that the trimeric clustering of receptors is the primary initiating event for signal induction.  We 
have recently developed a novel inhibitor of RANKL-induced osteoclast formation and function 
relying on the manipulation of receptor oligomerization (see Chapter 2).  In the process of 
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engineering a single-chain RANKL capable of antagonizing RANK signaling, we generated a 
panel of increased affinity RANKL mutants that allowed our construct to out-compete wild-type 
(WT) RANKL binding.  In the present exercise, we sought to understand the relationship 
between binding affinity and biological function downstream of receptor ligation.  We utilized 
our panel of RANKL mutants with RANK affinities increased by 15- to 500-fold. Increased 
RANKL affinity for RANK displays a biphasic effect on osteoclastogenesis in vitro, reaching 
optimal activity at approximately 15-fold higher affinity than WT. These findings provide 
insights into the relationship between affinity and agonist function, raising the possibility that 
variants with even higher affinities may display antagonistic properties relevant for the design of 
future TNFSF-based therapies.  
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3.3 Materials and Methods:  
Production of mammalian RANKL protein:  Constructs used for transient transfection of 
RANKL (see Chapter 2) or OPG (22) were previously described.  For mammalian protein 
production, suspension adapted 293-Freestyle cells (Life Technologies) were maintained in 
serum-free Freestyle 293 expression medium (Life Technologies) according to the 
manufacturer’s protocol. Cells were seeded at a density of 0.5x106/mL and transfected the next 
day using the cationic lipid polyethylenimine(23).  Supernatant was harvested four and seven 
days after transfection, 0.22uM filtered and equilibrated by the addition of 1/10 volume 10X 
phosphate buffered saline (Gibco) and 10mM imidazole.  The protein was captured on Ni-NTA 
Superflow resin (Qiagen) and washed using 10mM imidazole in PBS.  Protein was eluted in 
steps from 25-500mM imidazole.  Fractions containing purified protein were identified on 
coomassie stained SDS-PAGE.  Positive fractions were pooled and concentrated using a 
disposable YM30 centricon (Millipore). All proteins were sterile filtered for use in cell culture. 
Surface Plasmon Resonance (SPR):  All SPR experiments were performed on a Biacore T-100 
(GE Healthcare) using CM5 sensor chips and HBS-EP buffer.  To confirm receptor recruitment 
using scRANKL variants, 4,000 RU of WT-scRANKL or variant scRANKL were coupled to 
individual lanes, leaving one reference flow cell uncoupled. Experiments to determine kinetic 
affinity constants of RANKL variants for RANK or OPG were performed and analyzed as 
previously described (22). 
Generation of osteoclasts from primary bone marrow macrophages:  Long bones of eight 
week-old mice were flushed and the marrow subjected to red blood cell lysis.  The remainder of 
the whole marrow was cultured on petri dishes maintained at 37°C with 6% CO2 in alpha-mem 
containing 10% inactivated fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, (α-
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10 medium) supplemented with 1:10 CMG (conditioned medium supernatant containing 
recombinant M-CSF)(24).  Osteoclasts were differentiated in α-10 medium with 1:50 CMG and 
the relevant RANKL variant.  Alternatively, osteoclasts were differentiated in the presence of 
100ng/mL of mutant RANKL with varying concentrations of monomeric OPG. 
Detection of osteoclast formation:  Cells were fixed in 4% paraformaldehyde in PBS for 15 
minutes and stained for the tartrate resistant acid phosphatase (TRAP) using a kit (Sigma. 
Quantitative assessment of TRAP activity was performed using the fluorescent phosphatase 
substrate ELF-97 (Molecular Probes).  Fixed cells were incubated with 100uM ELF-97 in 90mM 
citrate buffer pH=4.8, 80mM sodium tartrate for 15 minutes at room temperature.  The reaction 
was stopped by the addition of sodium hydroxide and fluorescence was visualized using the 
345/530 excitation/emission filter on a Spectramax M2 plate reader.  
Quantitative real-time PCR:  To quantitate mRNA markers of osteoclast formation, RNA was 
isolated from cultured cells according to the manufacturer’s protocol (Qiagen RNeasy miniprep 
kit).  Equal amounts of RNA were used to perform reverse transcription (Bio-rad iScript) and 
quantitative real-time PCR was performed using Eva Sso fast qPCR Sybr green kit (Bio-rad) 
using a 7500 fast machine (ABI).  Data was analyzed according to the delta-delta Ct method and 
normalized to a control containing no RANKL addition (labeled BMM).  Primers used were as 
follows: CatK (Forward: 5’-ATGTGGGTGTTCAAGTTTCTGC-3’, Reverse: 5’-
CCACAAGATTCTGGGGACTC-3’), NFATc1 (Forward: 5’-CCCGTCACATTCTGGTCCAT-
3’, Reverse: 5’-CAAGTAACCGTGTAGCTGCACAA-3’), TRAP (Forward: 5’-
CAGCTCCCTAGAAGATGGATTCAT-3’, Reverse: 5’GTCAGGAGTGGGAGCCATATG), 
beta3 (Forward: 5’-TTCGACTACGGCCAGATGATT-3’, Reverse: 5’-
GGAGAAAGACAGGTCCATCAAGT-3’). 
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Detection of Collagen Fragments from Culture Supernatant:  Pre-osteoclasts were generated 
form primary bone marrow macrophages in the presence of wild-type RANKL and lifted with 
trypsin/EDTA.  Equal numbers of pre-osteoclasts were plated on bovine bone slices in the 
presence of RANKL variants at 100ng/mL or doses for two additional days.  The release of 
collagen peptides into the culture supernantant was detected by ELISA according to the 
manufacturer's protocol (IDS). 
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3.4 Results 
Osteoclast formation in vitro driven by RANKL mutants:  In Chapter 2 of this thesis, we 
reported the affinity maturation of RANKL for its signaling receptor RANK using yeast surface 
display.  We estimated the affinities of several RANKL mutants using titration curves generated 
on the surface of RANKL-displaying yeast cells, showing a range from 15- to 500-fold increase 
relative to wild-type.   Of note, these variants were identified on a background of two mutations 
that allowed for the increased production of our proteins of interest without affecting the affinity 
for RANK.  These two mutations (C220S and I246E) were termed “solubility mutants,” hence 
RANKL containing only these two mutations will be referred to as solubility-mutant WT 
RANKL (WT-SM).  Importantly, both WT RANKL and WT-SM RANKL are equally capable of 
forming osteoclasts in vitro (Supplemental Figure 3.S1A).  
First, we confirmed the affinities for RANK and OPG of each RANKL variant using 
surface plasmon resonance (Table 1).  As described above (see Chapter 2, Figure 2.11), the 
single point mutant Q236H increased the affinity for RANK by approximately 15-fold while a 
quadruple mutation (K194E/Q236H/F269Y/H270 or “KQFH”) increased the affinity by roughly 
500-fold.  Here we show that K194E alone also increases the affinity for RANK, though less 
than 2-fold (Table 1).  The combination of K194E/Q236H (“KQ”) increases binding to the 
receptor by 20-fold, and K194E/Q236H/F269Y (“KQF”) by 50-fold.  Thus, we have established 
a panel of RANKL variants ranging from a slight increase in affinity up to a 500-fold increase in 
binding to RANK.  We also confirmed that all proteins containing the Q236H mutation have 
dramatically reduced binding to OPG.  Interestingly, the single point mutant K194E decreases 
binding to OPG by approximately 4-fold. 
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Next, we sought to determine the osteoclastogenic capacity of our RANKL variants with 
increased affinity for RANK.  To this end, we cultured bone marrow macrophages with M-CSF 
and increasing concentrations of RANKL, then stained for mature cells (Figure 3.1A).  
Osteoclastogenesis was quantitated using a TRAP activity assay to fit EC50 values of each 
RANKL variant. (Figure 3.1B,C).  A single point mutation added to WT-SM, K194E-SM, is 
approximately twice as efficient at generating mature osteoclasts.  Q236H-SM possessing a 15-
fold increase in affinity for RANK, displayed the most robust increase in activity (compare 
average WT-SM EC50 = 9.78ng/mL versus Q236H-SM EC50 = 1.46 ng/mL).  Interestingly, 
further increases in affinity up to 50-fold higher than WT RANKL did not more efficiently 
promote osteoclastogenic potency.  Moreover, KQFH-SM RANKL, with a 500-fold increase in 
affinity for RANK, does not generate osteoclasts as efficiently as Q236H-SM, though is still 
outperforms WT-SM RANKL.  In agreement with osteoclast formation as assessed by TRAP 
stain and TRAP activity, osteoclastogenic markers induced by RANKL variants show a similar 
affinity-dependent biphasic effect (Figure 3.1D,E).  Hence, RANKL/RANK affinity exerts a 
biphasic effect of RANKL affinity for RANK on osteoclast formation in vitro, such that 
extremely high binding is not as optimal as an intermediate increase. 
Resistance of RANKL mutants to exogenously added OPG.  During the development of a 
single-chain RANKL inhibitor possessing altered RANK affinities, we sought to simultaneously 
decrease the capacity of the RANKL variants to bind the decoy receptor OPG.  To that end, the 
mutations we OPG affinities of mutations we identified  substantially decreased as assessed by 
yeast surface display and confirmed by SPR (Table 1).  We next sought to determine if these 
mutants are more resistant to the addition of exogenous OPG in osteoclastogenic conditions in 
vitro.  Interestingly, the solubility mutations which did not affect binding to RANK, exhibit a 
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roughly 10-fold decrease in OPG affinity (Supplemental Figure 3.S1B).  In TRAP activity assays 
for osteoclast formation, we observed a functional consequence of this affinity change results in 
a 6-fold greater resistance to the addition of monomeric, cytokine-binding OPG fragment.  
Specifically, the OPG IC50 inhibiting WT RANKL-induced osteoclastogenesis is 141.6ng/mL, 
while the OPG IC50 inhibiting  WT-SM RANKL is 824.3ng/mL.  Representative TRAP stained 
images of bone marrow macrophages cultured in the presence of increasing amounts of OPG 
with a constant amount of each RANKL variant demonstrate that all mutations incorporating 
Q236H are completely resistant to the effects of OPG (Figure 3.2).  RANKL K194E-induced 
osteoclastogenesis was inhibited slightly at the highest doses of the decoy receptor, though not 
sufficient to permit the assessment of an IC50 value given the range of OPG concentrations used.  
Therefore, despite the similar binding footprints of OPG and RANK on the cytokine RANKL, it 
is possible to impose opposite effects on cellular function using receptor selective mutations. 
Altered signaling to key osteoclastogenic mediators is enhanced by high affinity RANKL 
variants.  To determine whether the osteoclastogenic effects of progressively increasing RANKL 
affinity for RANK reflects altered signaling, we stimulated bone marrow macrophages with 
RANKL variants.  We then assessed the phosphorylation of two crucial signaling events in 
osteoclast differentiation, namely phosphorylation of NF-kB and the MAP kinase, p38 (Figure 
3.3A,B; Supplemental Figure 3.S1C).  The signaling induced by Q236H-SM and KQFH-SM 
RANKL is more robust than that of WT-SM RANKL, and maximizes earlier.  As with osteoclast 
formation, KQFH-SM RANKL is not as potent as Q236H-SM RANKL at phosphorylating these 
key osteoclastogenic molecules.  Thus, like osteoclastogenesis, per se, the RANKL/RANK 
interaction optimizes signal transduction at intermediate, rather than extremely high, affinities. 
83 
 
Enhanced osteoclast function in vitro with increased RANKL affinity variants.  RANKL 
not only promotes osteoclast formation, but also stimulates the resorption of bone by the mature 
cell.  To determine if osteoclast function is also dictated by RANK/RANKL affinity, we cultured 
bone marrow macrophages on plastic in equal amounts of WT-RANKL for four days to generate 
pre-osteoclasts.  We then lifted and plated an equal number of cells on bovine bone slices in low- 
or high-dose RANKL variants.  After 24 hours, we assessed collagen fragment release into the 
media (Figure 3.4; Supplemental Figure 3.S1D).  Despite normalized osteoclast numbers, 
Q236H-SM RANKL activates mature cells to resorb bone more than WT-SM RANKL, 
indicating that this variant not only enhances differentiation but also functional activity. 
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3.5 Discussion 
 From the discovery of lymphotoxin-beta and the TNF/TNFR1/TNFR2 ligand/receptor 
pairs almost thirty years ago, the role of TNFSF members in human disease has continued to 
grow.  The expanding role of this protein family has also led to an increased interest in targeting 
cytokine or receptor to modulate autoimmunity, anti-tumoral activity, and bone mass.  Current 
FDA-approved drugs comprise antibodies or receptor-Fc fragments that act by functionally 
removing the cytokine from the system (13).  However, several TNFSF members bind more than 
one receptor (1), and there are circumstances in which the specific targeting of the actions of an 
individual receptor would be desirable.  These and other aspects of this complex protein family 
may contribute in part to the disparities sometimes observed between pre-clinical and clinical 
trials focused at neutralizing cytokine. 
A striking example is TNF-alpha, whose initial blockade in the pre-clinical multiple 
sclerosis model, experimental autoimmune encephalitis, was protective (25).  However, some 
patients with multiple sclerosis treated with Lenercept (soluble-TNFR IgG-fusion protein) 
experienced an increased number of disease exacerbations with more severe neurological deficits 
(26).  Additionally, pre-clinical studies using various models of sepsis yielded dramatically 
different results following TNF cytokine neutralization (27) depending in part on the model 
utilized.  Indeed, clinical trials based on the endotoxin murine model of sepsis suggested that 
TNF blockade may be beneficial for survival, though the human experience did not propagate 
these results (28).  Indeed, a protective effect of TNFR2 and detrimental effect of TNFR1 
signaling has been implicated not only in septic shock (29, 30), but also in LPS-, RANKL-, or 
TNFa-mediated bone resorption (31-33).  Thus, recent efforts using antibodies specifically 
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targeting TNFR1 may help provide impetus for the design of future therapeutics aimed at 
receptor specific targeting (34). 
An alternative to antibody-mediated modulation of these signaling pathways is the 
development of receptor-selective cytokine mutants.  Our present study elucidates the in vitro 
functional outcomes of modulating RANKL affinity for its signaling receptor RANK and its 
decoy receptor OPG.  We show that initially, moderate increases in affinity for RANK lead to a 
substantial increase in function as measured by osteoclast formation, signaling, and bone 
resorption in vitro.  However, further increases to very high affinity RANKL mutants produce 
less efficient downstream actions.  To our knowledge, this is the first evidence that RANK 
signaling can be optimized by increasing affinity.  However, there is not a linear relationship 
between affinity and functional outcome.  This observation is, however, consistent with previous 
studies exploring the relationship between T-cell receptor (TCR): peptide-MHC affinity and 
biological events (35-37).  Additionally, there is some evidence that there may be a non-linear 
relationship between TNF receptor binding and functional outcome (38), though the reported 
affinities do not represent single-site binding events, making interpretation of this data difficult. 
Our results suggest that the use of forward-genetic approaches to identify novel mutations 
within the TNFSF can allow for the generation of receptor-selective, highly efficient agonists.  
The supposition that selective inhibition and/or activation of TNF receptors   may be beneficial is 
supposed by the effect of TNFR2 agonism on the complications of experimental type I diabetes 
(39, 40).  A scenario in which signal-transduction optimized, TNFR2 agonist that does not bind 
to and alter the TNFR1 pathway could provide a novel avenue for the treatment this or other 
autoimmune and cardiovascular diseases.  This strategy could be applicable to several other 
TNFSF ligand/receptor pairs.  Because of the non-linear relationship between RANKL/RANK 
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affinity and function, the development of receptor agonists within the protein family through 
non-biased, forward genetic approaches may necessitate the use of functional screens rather than 
affinity-based screens (41).   
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3.7 Figure Legends 
Table 3.1.  Kinetic affinity parameters of RANKL mutants binding to monomeric RANK or 
OPG were determined using SPR.  *Previously reported (see Chapter 2).  Values represent the 
averages of three independent experiments. 
Figure 3.1.  Osteoclastogenic potential of RANKL variants.  (A)The capacity of mutant RANKL 
proteins to generate osteoclasts from bone marrow macrophages was assessed by TRAP stain 
using increasing amounts of purified RANKL protein.  (B) Titration curves of osteoclastogenesis 
were fit using a four-parameter dose-response curve.  (C) EC50 values calculated from the curve 
fits in (B). Assessment of osteoclastogenic markers by real-time detection of NFATc1 (D) or β3 
integrin (E) mRNA levels. 
Figure 3.2. Ability of monomeric OPG to inhibit RANKL-induced osteoclast formation.  
Varying amounts of monomeric OPG were added to cultures containing 100ng/mL of each 
RANKL variants and osteoclasts were stained for TRAP.   
Figure 3.3.  Signaling downstream of RANKL variants.  (A)  Bone marrow macrophages were 
serum starved and stimulated with 100ng/mL WT-SM, Q236H-SM, or KQFH-SM RANKL.  
The phosphorylation of NF-kB and p38 were assessed by western blot.  (B)  Densitometry of 
western blots depicted in (A). 
Figure 3.4. Activation of mature osteoclasts by RANKL variants.  After several days in culture 
with WT RANKL, osteoclasts were plated in equal numbers on bovine bone slices and 
stimulated with WT-SM, Q236H-SM, or KQFH-SM.  The release of collagen fragments (CTx) 
was measured after 24 hours. 
Supplemental Figure 3.S1.  Comparison of WT RANKL and WT-SM RANKL.  Differences 
and similarities between the ability of WT RANKL and WT-SM RANKL to induce 
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osteoclastogenesis (A), resist the inhibitory activity of OPG (B), initiate RANK signaling (C) 
and resorb bone in vitro (D). 
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4.1 Conclusions 
Generation of single-chain RANKL: The primary aim of this thesis was to provide evidence for 
the receptor oligomeric state of RANK receptor necessary and sufficient to induce pro-osteoclastogenic 
signals.  A secondary goal was to use this information to develop a novel strategy for RANK inhibition, 
which may be broadly applicable to TNF receptor superfamily inhibition.  Despite the assumption that 
trimeric TNFSF ligands act by clustering three receptors to initiate signal transduction, evidence 
suggesting the importance of ligand-independent receptor association (1-3), the formation of signaling-
competent receptor dimers (4), or higher-order clustering (5-8) has challenged this simple model.  Within 
RANK signaling, reports have suggested both ligand-independent receptor association (9) and signaling 
through dimeric receptors (10), though these studies are accompanied by the major caveats inherent with 
receptor overexpression or the use of artificial chimeric constructs. 
 To circumvent the need for overexpressed or chimeric receptor, we approached the question of 
receptor recruitment using manipulation of the cytokine itself.  Because the N- and C-termini of RANKL 
are located in close physical proximity (11), we were able to covalently link each monomer together using 
glycine/serine repeats.  We demonstrated that this single-chain version of RANKL (scRANKL) was 
equally capable of generating osteoclasts and had the predicted molecular weight of a trimer without 
evidence of monomeric species on reducing gel.   
Probing the signaling-competent receptor oligomeric state of RANK: With this tool in hand, 
we generated single- and double-blocked versions of scRANKL capable of only recruiting two or one 
RANK receptors, respectively. To this end, we identified mutations in RANKL that prevent RANK 
binding.  Initial studies using monomeric RANK to assess decreased binding indicated that the RANKL 
variant R222Q may be an appropriate mutation to use for this purpose.  However, binding studies using 
an Fc-tagged version of RANK increased the sensitivity of the assay, allowing us to elucidate that, 
although the affinity of R222Q was substantially lower than WT RANKL, its binding to RANK was not 
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absent.  Therefore, we used the co-crystal structure of RANK/RANKL to design loop insertion mutants in 
the hopes that these variants would prevent receptor recruitment.  Most promising was the CD loop of 
RANKL, which contains an i+3 beta turn making it possible that amino acids inserted proximal to this 
ordered structural region would yield a RANK null-binding version.  Indeed, all mutations with no 
detectable binding to RANK-Fc contained various insertions in the CD-loop.  Interestingly, the analogous 
loop in human RANKL (termed the DE loop) is the target of the RANKL-neutralizing therapeutic 
monoclonal antibody Denosumab (12).  These findings have important implications for the general 
applicability of this single-chain approach to studying receptor oligomerization, as steric hinderance of 
receptor docking to generate a complete null-binder rather than to rely on individual point mutations. 
 Having identified a RANK receptor blocking mutant, we generated single- and double-block 
scRANKL and assessed osteoclastogenesis. Formation of mature cells by each scRANKL variant 
demonstrate that single-block, with two available receptor recruitment sites, is capable of generating 
osteoclasts while double-block is not.  This suggests that the occupancy of RANKL by three RANK 
receptors is not absolutely required to induce osteoclastogenic signals, while recruitment of at least two 
receptors is necessary.  The number of osteoclasts generated by single-block scRANKL was never as high 
as that generated by WT scRANKL, and the EC50 value of single-block was increased 20-fold indicating 
that this state of receptor oligomerization is sub-optimal.  Because we had generated a version of 
scRANKL capable of binding receptor yet unable to induce osteoclastogenic signals, we asked if this 
protein could act as an inhibitor of WT RANKL-induced osteoclastogenesis.  Its inability to do so likely 
reflects the loss of avidity relative to WT RANKL, prompting us to utilize yeast surface display to 
identify RANKL mutants with increased affinity for RANK.  We demonstrated that the use of 
progressively decreasing amounts of monomeric RANK in combination with OPG competition could 
facilitate the isolation of variants with a range of affinities for RANK, including one RANKL mutation 
with a 500-fold increase in affinity driven largely by prolonged off-rate.  Importantly, these mutations do 
not meaningfully recognize the decoy receptor OPG. 
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 The inclusion of medium- or high-affinity variants into the intact binding sites in scRANKL 
allowed us to observe that single-block RANKL with an increase in affinity at these two receptor 
recruitment sites generates fewer osteoclasts.  Indeed, the ability of single-block scRANKL to generate 
osteoclasts may be facilitated by the rapid off rate at the two receptor binding sites.  This may allow for 
the recruitment of additional RANK receptor, ultimately leading to higher order clustering.  Our 
observation that increasing the time required for single-block scRANKL variants to dissociate diminishes 
osteoclastogenesis supports this model.  Finally, single-block RANKL with high affinity at the intact sites 
is an effective inhibitor of RANKL-mediated osteoclast formation. 
One important caveat to these experiments is the method used for protein purification and the 
possibility of ligand heterogeneity.  Initial studies using CDins mutant RANKL purified from bacteria 
demonstrated no detectable binding to RANK-Fc, yet considerable phosphorylation of NF- B.  We found 
a lack of responsiveness to CDins RANKL-induced signals when using TLR4-KO macrophages, 
indicating that this phosphorylation was the result of the exquisite sensitivity of macrophages to even 
minute amounts of LPS carried over during purification.  Therefore, we developed a method for 
producing WT RANKL and scRANKL proteins secreted from mammalian cells into serum-free media.  
Purification was performed with an attempt to remain LPS-free, necessitating avoidance of a final size 
exclusion chromatography step.  However, when we examined the size exclusion profiles of our 
scRANKL protein, we observed a small, but significant, higher molecular weight species.  This could be 
explained by two possibilities.  First, the solubility mutant version of RANKL contains two predicted 
glycosylation sites per monomer and migrates as two bands on reducing gel when purified from 
mammalian cells, but not when purified from bacteria.  By two-dimensional gel electrophoresis, the one 
predicted glycosylation site of murine TNF  was shown to add as much as 10 – 20 kDa of sugar per 17 
kDa monomer (13) when secreted from stimulated macrophages.  Therefore, given the two available 
glycosylation sites in RANKL, it seems possible that a substantial, though potentially heterogeneous, 
amount of carbohydrate may be present on scRANKL.   
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The second possibility is that, by the use of 12 amino acid long linkers between each scRANKL 
monomer, scRANKL may unfold and re-fold as two or more associated proteins.  One argument against 
this scenario is the RANKL monomer-trimer molar association constant of 6.5 x 10
20 
M
-2
, indicating that 
once a trimer has formed, it is highly unlikely to dissociate from this form (14).  Therefore, generation of 
an integrated oligomeric scRANKL species would necessitate the formation of higher order variants 
during initial protein translation and folding.  The relevance of this possibility is to our findings that 
single-block scRANKL is capable of generating osteoclasts, which is in opposition to the classic model of 
trimeric receptor clustering as initiating signal transduction.  When we performed size exclusion 
chromatography to isolate a conservatively monomeric species of scRANKL, we still observed osteoclast 
formation, albeit at levels lower than unsized protein (not shown).  Here, scRANKL would have had to 
unfold post-purification and refold into a dimeric species to allow for the possibility that the higher 
molecular weight version of scRANKL is a “domain-swapped” variant.  Again, given the molar 
association constant, this scenario seems highly unlikely though cannot be absolutely excluded at this 
time. Finally, this potential dimeric species of single-block scRANKL would have to consistently fold in 
such a way that the 120° receptor binding groove geometry was maintained with proper binding site 
orientation, as it has been shown that the integrity of this groove is important for receptor recruitment 
(15). It is this author’s view that our conservative collection of the lowest molecular weight portion of 
scRANKL during size exclusion chromatography completely removed the glycosylated version of the 
protein, which may have affected either its binding properties or its solubility in solution throughout the 
course of in vitro experiments thus explaining the reduced osteoclastogenesis when using sized versus 
non-sized protein. 
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4.2 Future directions 
Optimization of scRANKL protein: To resolve the issue of observed higher molecular weight 
species of scRANKL, it may be possible to treat scRANKL proteins with inhibitors of glycosylation 
during transfection and protein production and test the ability of this non-glycosylated version of single-
block scRANKL to present as a mono-dispersed fraction on a size exclusion column and/or generate 
osteoclasts.  It may also be possible that there exists an ideal linker length which prevents any potential 
folded version of scRANKL other than the monomeric version, yet allows for adequate protein expression 
levels.  Lastly, previous reports of single-chain TNF utilized molecular dynamics simulations to provide 
guidance for optimizing linker length (4).  As flexible loops that are either too short or too long have been 
suggested to play a role in the domain swapping of certain proteins (16), it may be important to more 
rigorously determine what version of scRANKL would allow enough flexiblility for proper folding 
without the possibility of generating oligomerized aggregates.   
Clinically Relevant Models of RANKL-driven bone loss:  Regardless of whether or not this 
important issue can be resolved, it remains that single-block scRANKL with high affinity at the intact 
binding sites is an effective inhibitor of RANKL-mediated osteoclast formation both in vitro and in vivo.  
We utilized a rapid bone loss model based on intraperitoneal injection of WT RANKL (17) which has 
limited clinical relevance.  It would be interesting to test the ability of single-block, RANK
high
 scRANKL 
to protect against ovariectomy-induced bone loss, a model used extensively in our laboratory (18-20).  
Additionally, RANKL has been implicated in not only the growth of mammary cancer (21-24) but also in 
the migration (25-27) and osteolysis of metastatic breast cancer (28).  Current evidence suggests that the 
inhibition of RANKL-mediated signaling may be beneficial at treating breast cancer skeletal metastases 
(29) and it would be interesting to see if our novel scRANKL inhibitor can act in a similar, or perhaps 
more effective, manner.  Indeed, the anti-RANKL monoclonal antibody Denosumab was recently 
approved for the treatment of breast cancer bone metastases (30).  Given that the in vitro IC50 values of 
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our novel construct are almost 10-fold lower than that of Denosumab (scRANKL inhibitor IC50 = 0.2 nM 
versus denomsumab IC50 = 1.64nM), it may be possible to achieve therapeutic benefit with substantially 
lower levels of inhibitor. The further evaluation of single-block, RANK
high
 as an inhibitor of RANKL-
mediated pathology in vivo will necessitate the determination of phamacodynamic and pharmacokinetic 
parameters of this protein.  Lastly, as all residues involved in generating the blocking and high affinity 
mutations in murine RANKL are conserved in human RANKL, it would be interesting to generate the 
human version of this novel inhibitor and test it in the ovariectomized cynomologous monkey model, an 
important non-clinical animal model for RANKL inhibition (31, 32). 
Inhibition of other TNF receptors using the single-chain approach:  RANKL is a member of 
the TNF superfamily and binds to two different receptors (RANK and OPG) with divergent biological 
effects.  Our approach using a combination of blocking and high affinity mutations for RANK together 
with absent OPG binding, has allowed us to generate an efficient and selective RANK inhibitor.  Several 
other TNFSF members display receptor promiscuity, including TNF , which is capable of binding 
TNFR1 and TNFR2.  TNF  is involved in a wide variety of pathologies, included rheumatoid arthritis, 
sepsis, Crohn’s disease (33).  This has led to the development of several TNF antagonists, including an 
anti-TNF monoclonal antibody (Infliximab, ex) and soluble receptor fragment (Etanercept) (34).  These 
therapies, which result in removal of all cytokine-induced signals, are associated with significant 
morbidity including increased risk for infectious disease and malignancy (35-37).  This has prompted 
interest in the selective antagonism of TNFR1 over TNFR2 (38-41).  Because the binding modes of 
RANKL with RANK and OPG are very similar to the inferred or reported binding modes of TNF  with 
TNFR1 and R2 (42-44), it seems likely that a similar approach combining steric blockade of receptor 
docking with forward genetic screens to identify high affinity mutations for TNFR1 that do not recognize 
TNFR2 may succeed.  It is even possible to begin this yeast surface display undertaking with one of 
several previously described mutations that differentially affect TNFR1 and TNFR2 binding (45, 46).   
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One important caveat to any future use of this single-chain strategy is the necessity for any 
blocking and high affinity mutations to be located on the same side of the binding groove.  Regardless of 
the orientation of folding (right- or left-handed), having these mutations occupy the same side of the cleft 
contributed by each monomer ensures that each interface can be individually mutated (Figure 4.1).  Our 
yeast surface display efforts identified four point mutations that increased the affinity for RANK while 
decreasing the affinity for OPG, three of which are on the same side of the interface as the receptor 
blocking CD-loop (K194E, F269Y, and H270Y).  Fortunately, the fourth mutation, which was not on this 
side, could equally participate in the formation of a blocking or a high affinity interaction with RANK.  
For human TNF , a commonly used TNFR1-selective mutation is R32W/S86T.  However, this double 
point-mutant straddles both sides of the binding groove, making it an unattractive candidate to initiate a 
yeast surface screen.  Alternatively, Y87Q dramatically reduces the affinity for both receptors.  Therefore, 
it is intriguing to speculate that S86T/Y87Q may be an ideal TNFR1 receptor blocking mutation that also 
decreased TNFR2 affinity, while S86T alone might be a useful mutation to begin a search for TNF  
variants with selective increased TNFR1 affinity. 
Biphasic effect of RANKL/RANK affinity on osteoclast formation and function: Having 
identified RANKL mutations with a range of affinities for RANK, but decreased binding to OPG, we 
tested the ability of each variant to form osteoclasts in vitro.  We find that increasing the affinity for 
RANK by 15 – 50 fold leads to optimal activation of RANK as assessed by phosphorylation of 
downstream signals and EC50 values of osteoclast formation.  Interestingly, a further increase to 500-fold 
greater than WT RANKL reverses this trend.  Because the differences in affinity between these variants is 
reflected primarily in an longer off-rate, we can conclude that optimal RANK signaling necessitates not 
only RANKL association but the ability to dissociate.  This phenomenon has been observed in other 
signaling systems, most notably in T-cell receptor (TCR) signaling (47-49).  The observation that T-cell 
triggering occurs in an optimized peptide:MHC affinity window largely guided by variations in off-rate 
prompted the postulation of a “serial engagement” model (50).  In this scenario, the relatively rapid 
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dissociation of TCR from peptide:MHC facilitates the sequential and monovalent triggering of many T-
cell receptors.  As higher order clustering has been implicated for the signal transduction of other TNFSF 
members (5-8), we posit that RANK signaling is facilitated by the rapid off-rate of WT RANKL, which 
acts to cluster individual receptors via serial engagement.   
High Affinity RANKL Variants: These findings may not only inform our understanding of 
RANK receptor signaling, they may also serve as the basis for developing novel inhibitors of this 
pathway.  Although the largest increase in affinity for RANK that we identified from yeast surface 
display was 500-fold, this unbiased form of protein engineering has generated variants with as much as 
40,000-fold (51) or even 1 million-fold (52) higher affinities in other contexts.  What might the functional 
consequences be of similarly affinity-matured variations of RANKL?  There is precedent for 
supraphysiologic binding of TCR to peptide:MHC losing agonist effect (47).  Additionally, a high-affinity 
IL-4 variant was converted to an antagonist by substitution of a single amino acid, indicating a decoupling 
between receptor binding and efficacy (53, 54).  The relevance of this finding to TNF  is unclear, as 
variants have been described with increased affinity leading to disparate effects on in vitro function 
depending on where the mutations clustered on the cytokine (43).   
 Currently, experiments are underway to determine the effect of optimal receptor signaling on 
osteoclast function in vivo using the intraperitoneal IP RANKL injection model described above.  
Demonstration of enhanced RANKL mediated signaling in vivo may provide rational for treating patients 
with osteoclast-poor osteopetrosis who have mutations in the gene encoding RANKL (55).  Alternatively, 
it would be interesting to search for mutations in these conserved, high affinity residues of RANKL in 
single-nucleotide polymorphism studies to determine whether genetic differences in bone mass and risk 
for osteoporosis may be linked to mutations that increase receptor binding to an optimized level.  Lastly, 
it would be interesting to explore the mechanism by which WT, intermediate affinity, and high affinity 
RANKL variants lead to different efficacies.  Is RANK receptor internalization necessary for downstream 
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signaling, and is this event optimal with 10- to 50-fold increases in affinity?  Are signaling events beyond 
receptor proximal targets altered in the context of altered binding kinetics?  These and other ongoing 
studies will add to our knowledge of how signals are initiating upon RANKL ligation of its receptor 
RANK.  
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4.4 Figure Legend 
Figure 4.1.  Receptor interfaces in scRANKL.  (A) Each RANKL monomer is labeled “A”, “B”, or “C” 
and is shown connected by the Gly/Ser linkers (orange lines).  The interfaces capable of accepting RANK 
receptor have been arbitrarily named “X”, “Y”, and “Z”.  The RANKL AA’, CD, and GH loops 
contribute to the side of the interface termed “L”, and the DE and EF loops contribute to the side termed 
“R”.  Depicted are two possible conformations of scRANKL, one that has folded with a right-handed 
orientation and one with a left-handed orientation.  The possible interfaces with corresponding 
contributions from each monomer are indicated below the diagram. (B) Single-block scRANKL provides 
one example of how individually mutated receptors can yield identical binding interfaces regardless of the 
right- or left-handed nature of scRANKL folding.  *Note that CDins from the “L” side of an interface 
combined with either a WT or Q236H (“Q”) contributed from the “R” side comprise a receptor blocking 
interface, while KFH from the “L” side combined with Q from the R side form a high affinity interface.  
(C)  Single-block, RANK
high
 scRANKL interfaces as in (B). 
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